Statements

Therapeutic response

Precision oncology relationships for therapeutic response.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Anastrozole	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Letrozole	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib	FDA
Sensitivity (Supports)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone	FDA
Sensitivity (Supports)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone	FDA
Sensitivity (Supports)	KRAS p.G12C	Non-Small Cell Lung Cancer	Adagrasib	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab emtansine	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab emtansine	FDA
Sensitivity (Supports)	EGFR Somatic variants	Non-Small Cell Lung Cancer	Afatinib	FDA
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Alectinib	FDA
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Alectinib	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PIK3CA Somatic variants	Invasive Breast Carcinoma	Alpelisib, Fulvestrant	FDA
Sensitivity (Supports)	HER2-negative, PIK3CA Somatic variants, PR positive	Invasive Breast Carcinoma	Alpelisib, Fulvestrant	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PIK3CA Somatic variants, PR positive	Invasive Breast Carcinoma	Alpelisib, Fulvestrant	FDA
Sensitivity (Supports)	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Amivantamab, Carboplatin, Pemetrexed	FDA
Sensitivity (Supports)	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Amivantamab	FDA
Sensitivity (Supports)	PML::RARA	APL with PML-RARA	Arsenic trioxide	FDA
Sensitivity (Supports)	PML::RARA	APL with PML-RARA	Arsenic trioxide	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Asciminib	FDA
Sensitivity (Supports)	ABL1 p.T315I, BCR::ABL1	Chronic Myelogenous Leukemia	Asciminib	FDA
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Atezolizumab	FDA
Sensitivity (Supports)	PD-L1 >= 50%	Non-Small Cell Lung Cancer	Atezolizumab	FDA
Sensitivity (Supports)	PD-L1 >= 10% TIIC	Non-Small Cell Lung Cancer	Atezolizumab	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab, Carboplatin, Paclitaxel	FDA
Sensitivity (Supports)	EGFR Somatic variants	Non-Small Cell Lung Cancer	Atezolizumab	FDA
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Atezolizumab	FDA
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Atezolizumab, Cobimetinib, Vemurafenib	FDA
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Atezolizumab, Cobimetinib, Vemurafenib	FDA
Sensitivity (Supports)	PDGFRA p.D842V	Gastrointestinal Stromal Tumor	Avapritinib	FDA
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Binimetinib, Encorafenib	FDA
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Binimetinib, Encorafenib	FDA
Sensitivity (Supports)	BRAF p.V600E	Non-Small Cell Lung Cancer	Binimetinib, Encorafenib	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole	FDA
Sensitivity (Supports)	CD19 +	Acute Lymphoid Leukemia	Blinatumomab	FDA
Sensitivity (Supports)	CD19 +	Acute Lymphoid Leukemia	Blinatumomab	FDA
Sensitivity (Supports)	CD19 +, not BCR::ABL1	Acute Lymphoid Leukemia	Blinatumomab	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Bosutinib	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Bosutinib	FDA
Sensitivity (Supports)	CD30 +	Anaplastic Large Cell Lymphoma	Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone	FDA
Sensitivity (Supports)	CD30 +	Anaplastic Large Cell Lymphoma	Brentuximab vedotin	FDA
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Brigatinib	FDA
Sensitivity (Supports)	HER2-positive	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PIK3CA Somatic variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	HER2-negative, PIK3CA Somatic variants, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PIK3CA Somatic variants, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	AKT1 Somatic variants, ER positive, HER2-negative	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	AKT1 Somatic variants, HER2-negative, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	AKT1 Somatic variants, ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	AKT1 amplification, ER positive, HER2-negative	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	AKT1 amplification, HER2-negative, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	AKT1 amplification, ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PTEN nonsense variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	HER2-negative, PR positive, PTEN nonsense variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive, PTEN nonsense variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PTEN frameshift variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	HER2-negative, PR positive, PTEN frameshift variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive, PTEN frameshift variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PTEN splice site variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	HER2-negative, PR positive, PTEN splice site variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive, PTEN splice site variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PTEN deletion	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	HER2-negative, PR positive, PTEN deletion	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive, PTEN deletion	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	MET Exon 14 (Splice Site)	Non-Small Cell Lung Cancer	Capmatinib	FDA
Sensitivity (Supports)	MET Exon 14 (Deletion)	Non-Small Cell Lung Cancer	Capmatinib	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR, Wild type ROS1	Non-Small Cell Lung Cancer	Carboplatin, Cemiplimab, Pemetrexed	FDA
Sensitivity (Supports)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR, dMMR	Non-Small Cell Lung Cancer	Cemiplimab	FDA
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Ceritinib	FDA
Sensitivity (Supports)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab, Fluorouracil, Irinotecan	FDA
Sensitivity (Supports)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab, Irinotecan	FDA
Sensitivity (Supports)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab	FDA
Sensitivity (Supports)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib	FDA
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Cobimetinib, Vemurafenib	FDA
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Cobimetinib, Vemurafenib	FDA
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Crizotinib	FDA
Sensitivity (Supports)	v::ROS1	Non-Small Cell Lung Cancer	Crizotinib	FDA
Sensitivity (Supports)	v::ALK	Anaplastic Large Cell Lymphoma	Crizotinib	FDA
Sensitivity (Supports)	v::ALK	Inflammatory Myofibroblastic Tumor	Crizotinib	FDA
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Dabrafenib	FDA
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib	FDA
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib	FDA
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib	FDA
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Letrozole	FDA
Sensitivity (Supports)	BRAF p.V600E	Non-Small Cell Lung Cancer	Dabrafenib, Trametinib	FDA
Sensitivity (Supports)	BRAF p.V600E	Anaplastic Thyroid Cancer	Dabrafenib, Trametinib	FDA
Sensitivity (Supports)	BRAF p.V600E	Any solid tumor	Dabrafenib, Trametinib	FDA
Sensitivity (Supports)	BRAF p.V600E	Low-Grade Glioma, NOS	Dabrafenib, Trametinib	FDA
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Dacomitinib	FDA
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Dacomitinib	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Dasatinib	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Dasatinib	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Dasatinib	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Dasatinib	FDA
Sensitivity (Supports)	BCR::ABL1	Acute Lymphoid Leukemia	Dasatinib	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Dasatinib	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Dasatinib	FDA
Sensitivity (Supports)	BCR::ABL1	Acute Lymphoid Leukemia	Dasatinib	FDA
Sensitivity (Supports)	dMMR	Endometrial Carcinoma	Carboplatin, Dostarlimab, Paclitaxel	FDA
Sensitivity (Supports)	MSI-H	Endometrial Carcinoma	Carboplatin, Dostarlimab, Paclitaxel	FDA
Sensitivity (Supports)	dMMR	Endometrial Carcinoma	Dostarlimab	FDA
Sensitivity (Supports)	dMMR	Any solid tumor	Dostarlimab	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Pemetrexed, Tremelimumab	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Pemetrexed, Tremelimumab	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Gemcitabine, Tremelimumab	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Gemcitabine, Tremelimumab	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Nab-paclitaxel, Tremelimumab	FDA
Sensitivity (Supports)	dMMR	Endometrial Carcinoma	Carboplatin, Durvalumab, Paclitaxel	FDA
Sensitivity (Supports)	ER positive, ESR1 activating variants, HER2-negative	Invasive Breast Carcinoma	Elacestrant	FDA
Sensitivity (Supports)	IDH2 p.R140Q	Acute Myeloid Leukemia	Enasidenib	FDA
Sensitivity (Supports)	IDH2 p.R140L	Acute Myeloid Leukemia	Enasidenib	FDA
Sensitivity (Supports)	IDH2 p.R140G	Acute Myeloid Leukemia	Enasidenib	FDA
Sensitivity (Supports)	IDH2 p.R140W	Acute Myeloid Leukemia	Enasidenib	FDA
Sensitivity (Supports)	IDH2 p.R172K	Acute Myeloid Leukemia	Enasidenib	FDA
Sensitivity (Supports)	IDH2 p.R172M	Acute Myeloid Leukemia	Enasidenib	FDA
Sensitivity (Supports)	IDH2 p.R172G	Acute Myeloid Leukemia	Enasidenib	FDA
Sensitivity (Supports)	IDH2 p.R172S	Acute Myeloid Leukemia	Enasidenib	FDA
Sensitivity (Supports)	IDH2 p.R172W	Acute Myeloid Leukemia	Enasidenib	FDA
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Binimetinib, Encorafenib	FDA
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Binimetinib, Encorafenib	FDA
Sensitivity (Supports)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib	FDA
Sensitivity (Supports)	BRAF p.V600E	Non-Small Cell Lung Cancer	Binimetinib, Encorafenib	FDA
Sensitivity (Supports)	v::ROS1	Non-Small Cell Lung Cancer	Entrectinib	FDA
Sensitivity (Supports)	v::NTRK1	Any solid tumor	Entrectinib	FDA
Sensitivity (Supports)	v::NTRK2	Any solid tumor	Entrectinib	FDA
Sensitivity (Supports)	v::NTRK3	Any solid tumor	Entrectinib	FDA
Sensitivity (Supports)	FGFR3 p.R248C	Bladder Urothelial Carcinoma	Erdafitinib	FDA
Sensitivity (Supports)	FGFR3 p.S249C	Bladder Urothelial Carcinoma	Erdafitinib	FDA
Sensitivity (Supports)	FGFR3 p.G370C	Bladder Urothelial Carcinoma	Erdafitinib	FDA
Sensitivity (Supports)	FGFR3 p.Y373C	Bladder Urothelial Carcinoma	Erdafitinib	FDA
Sensitivity (Supports)	FGFR3::TACC3	Bladder Urothelial Carcinoma	Erdafitinib	FDA
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Erlotinib	FDA
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Erlotinib	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Everolimus, Exemestane	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Everolimus, Exemestane	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Everolimus, Exemestane	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant	FDA
Sensitivity (Supports)	ER positive	Invasive Breast Carcinoma	Fulvestrant	FDA
Sensitivity (Supports)	PR positive	Invasive Breast Carcinoma	Fulvestrant	FDA
Sensitivity (Supports)	ER positive, PR positive	Invasive Breast Carcinoma	Fulvestrant	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant, Ribociclib	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Ribociclib	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Ribociclib	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant, Palbociclib	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Palbociclib	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Palbociclib	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant	FDA
Sensitivity (Supports)	FGFR2::v	Intrahepatic Cholangiocarcinoma	Futibatinib	FDA
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Gefitinib	FDA
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Gefitinib	FDA
Sensitivity (Supports)	CD33 +	Acute Lymphoid Leukemia	Gemtuzumab ozogamicin	FDA
Sensitivity (Supports)	CD33 +	Acute Lymphoid Leukemia	Gemtuzumab ozogamicin	FDA
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Gilteritinib	FDA
Sensitivity (Supports)	FLT3 p.D835Y	Acute Myeloid Leukemia	Gilteritinib	FDA
Sensitivity (Supports)	FLT3 p.D835A	Acute Myeloid Leukemia	Gilteritinib	FDA
Sensitivity (Supports)	FLT3 p.D835E	Acute Myeloid Leukemia	Gilteritinib	FDA
Sensitivity (Supports)	FLT3 p.D835H	Acute Myeloid Leukemia	Gilteritinib	FDA
Sensitivity (Supports)	FLT3 p.D835N	Acute Myeloid Leukemia	Gilteritinib	FDA
Sensitivity (Supports)	FLT3 p.D835S	Acute Myeloid Leukemia	Gilteritinib	FDA
Sensitivity (Supports)	FLT3 p.D835V	Acute Myeloid Leukemia	Gilteritinib	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Imatinib	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Imatinib	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Imatinib	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Imatinib	FDA
Sensitivity (Supports)	BCR::ABL1	Acute Lymphoid Leukemia	Imatinib	FDA
Sensitivity (Supports)	BCR::ABL1	Acute Lymphoid Leukemia	Imatinib	FDA
Sensitivity (Supports)	PDGFRA rearrangements	Myelodysplastic Syndromes	Imatinib	FDA
Sensitivity (Supports)	PDGFRB rearrangements	Myelodysplastic Syndromes	Imatinib	FDA
Sensitivity (Supports)	not KIT p.D816V	Aggressive Systemic Mastocytosis	Imatinib	FDA
Sensitivity (Supports)	FIP1L1::PDGFRA	Chronic Eosinophilic Leukemia, NOS	Imatinib	FDA
Sensitivity (Supports)	CD117 +	Gastrointestinal Stromal Tumor	Imatinib	FDA
Sensitivity (Supports)	FIP1L1::PDGFRA	Gastrointestinal Stromal Tumor	Imatinib	FDA
Sensitivity (Supports)	FGFR2::v	Cholangiocarcinoma	Infigratinib	FDA
Sensitivity (Supports)	CD22 +	Acute Lymphoid Leukemia	Inotuzumab ozogamicin	FDA
Sensitivity (Supports)	MSI-H	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab	FDA
Sensitivity (Supports)	dMMR	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab	FDA
Sensitivity (Supports)	PD-L1 >= 1%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Ipilimumab, Nivolumab	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Pemetrexed	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Ipilimumab, Nivolumab, Pemetrexed	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Paclitaxel	FDA
Sensitivity (Supports)	IDH1 p.R132C	Acute Myeloid Leukemia	Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132G	Acute Myeloid Leukemia	Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132H	Acute Myeloid Leukemia	Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132L	Acute Myeloid Leukemia	Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132S	Acute Myeloid Leukemia	Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132C	Acute Myeloid Leukemia	Azacitidine, Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132G	Acute Myeloid Leukemia	Azacitidine, Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132H	Acute Myeloid Leukemia	Azacitidine, Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132L	Acute Myeloid Leukemia	Azacitidine, Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132S	Acute Myeloid Leukemia	Azacitidine, Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132C	Acute Myeloid Leukemia	Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132G	Acute Myeloid Leukemia	Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132H	Acute Myeloid Leukemia	Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132L	Acute Myeloid Leukemia	Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132S	Acute Myeloid Leukemia	Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132C	Myelodysplastic Syndromes	Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132G	Myelodysplastic Syndromes	Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132H	Myelodysplastic Syndromes	Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132L	Myelodysplastic Syndromes	Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132S	Myelodysplastic Syndromes	Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132C	Cholangiocarcinoma	Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132G	Cholangiocarcinoma	Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132H	Cholangiocarcinoma	Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132L	Cholangiocarcinoma	Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132S	Cholangiocarcinoma	Ivosidenib	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Capecitabine, Lapatinib	FDA
Sensitivity (Supports)	ER positive, HER2-positive	Invasive Breast Carcinoma	Lapatinib, Letrozole	FDA
Sensitivity (Supports)	HER2-positive, PR positive	Invasive Breast Carcinoma	Lapatinib, Letrozole	FDA
Sensitivity (Supports)	ER positive, HER2-positive, PR positive	Invasive Breast Carcinoma	Lapatinib, Letrozole	FDA
Sensitivity (Supports)	v::NTRK1	Any solid tumor	Larotrectinib	FDA
Sensitivity (Supports)	v::NTRK2	Any solid tumor	Larotrectinib	FDA
Sensitivity (Supports)	v::NTRK3	Any solid tumor	Larotrectinib	FDA
Sensitivity (Supports)	5q deletion	Myelodysplastic Syndromes	Lenalidomide	FDA
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Lorlatinib	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Capecitabine, Margetuximab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Eribulin, Margetuximab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Gemcitabine, Margetuximab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Margetuximab, Vinorelbine	FDA
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	FDA
Sensitivity (Supports)	FLT3 p.D835Y	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	FDA
Sensitivity (Supports)	FLT3 p.D835A	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	FDA
Sensitivity (Supports)	FLT3 p.D835E	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	FDA
Sensitivity (Supports)	FLT3 p.D835H	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	FDA
Sensitivity (Supports)	FLT3 p.D835N	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	FDA
Sensitivity (Supports)	FLT3 p.D835S	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	FDA
Sensitivity (Supports)	FLT3 p.D835V	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	FDA
Sensitivity (Supports)	FLT3 p.I836del	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	FDA
Sensitivity (Supports)	CDK12 oncogenic variants	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	FDA
Sensitivity (Supports)	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Mobocertinib	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Neratinib	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Capecitabine, Neratinib	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Nilotinib	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Nilotinib	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Nilotinib	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Nilotinib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Niraparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Niraparib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Niraparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Niraparib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Niraparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Niraparib	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Nivolumab, Paclitaxel	FDA
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Ipilimumab, Nivolumab	FDA
Sensitivity (Supports)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Olaparib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Olaparib	FDA
Sensitivity (Supports)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Olaparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Olaparib	FDA
Sensitivity (Supports)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	FDA
Sensitivity (Supports)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	FDA
Sensitivity (Supports)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib	FDA
Sensitivity (Supports)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib	FDA
Sensitivity (Supports)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib	FDA
Sensitivity (Supports)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib	FDA
Sensitivity (Supports)	HRD	Ovarian Epithelial Tumor	Bevacizumab, Olaparib	FDA
Sensitivity (Supports)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib	FDA
Sensitivity (Supports)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib	FDA
Sensitivity (Supports)	HRD	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib	FDA
Sensitivity (Supports)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib	FDA
Sensitivity (Supports)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib	FDA
Sensitivity (Supports)	HRD	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib	FDA
Sensitivity (Supports)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Olaparib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Olaparib	FDA
Sensitivity (Supports)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Olaparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Olaparib	FDA
Sensitivity (Supports)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	FDA
Sensitivity (Supports)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	FDA
Sensitivity (Supports)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib	FDA
Sensitivity (Supports)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	Pancreatic Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	Pancreatic Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	ATM pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	ATM oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	BARD1 pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	BARD1 oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	BRIP1 oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	BRIP1 pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	CDK12 pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	CDK12 oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	CHEK1 pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	CHEK1 oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	CHEK2 pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	CHEK2 oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	FANCL pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	FANCL oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	PALB2 pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	PALB2 oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	RAD51B pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	RAD51B oncogenic variants	Prostate Adenocarcinoma	Talazoparib	FDA
Sensitivity (Supports)	RAD51C pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	RAD51C oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	RAD51D pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	RAD51D oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	RAD54L pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	RAD54L oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone	FDA
Sensitivity (Supports)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone	FDA
Sensitivity (Supports)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone	FDA
Sensitivity (Supports)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone	FDA
Sensitivity (Supports)	IDH1 p.R132C	Acute Myeloid Leukemia	Olutasidenib	FDA
Sensitivity (Supports)	IDH1 p.R132G	Acute Myeloid Leukemia	Olutasidenib	FDA
Sensitivity (Supports)	IDH1 p.R132H	Acute Myeloid Leukemia	Olutasidenib	FDA
Sensitivity (Supports)	IDH1 p.R132L	Acute Myeloid Leukemia	Olutasidenib	FDA
Sensitivity (Supports)	IDH1 p.R132S	Acute Myeloid Leukemia	Olutasidenib	FDA
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Osimertinib	FDA
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Osimertinib	FDA
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Osimertinib	FDA
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Osimertinib	FDA
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Cisplatin, Osimertinib, Pemetrexed	FDA
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Carboplatin, Osimertinib, Pemetrexed	FDA
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Carboplatin, Osimertinib, Pemetrexed	FDA
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Cisplatin, Osimertinib, Pemetrexed	FDA
Sensitivity (Supports)	EGFR p.T790M	Non-Small Cell Lung Cancer	Osimertinib	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Letrozole, Palbociclib	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Palbociclib	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Palbociclib	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant, Palbociclib	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Palbociclib	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Palbociclib	FDA
Sensitivity (Supports)	Wild type HRAS, Wild type KRAS	Colorectal Adenocarcinoma	Fluorouracil, Oxaliplatin, Panitumumab	FDA
Sensitivity (Supports)	Wild type HRAS, Wild type KRAS	Colorectal Adenocarcinoma	Panitumumab	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Pembrolizumab, Pemetrexed	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Pembrolizumab, Pemetrexed	FDA
Sensitivity (Supports)	PD-L1 >= 1%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Pembrolizumab	FDA
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Pembrolizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Head and Neck Squamous Cell Carcinoma	Pembrolizumab	FDA
Sensitivity (Supports)	dMMR	Any solid tumor	Pembrolizumab	FDA
Sensitivity (Supports)	MSI-H	Any solid tumor	Pembrolizumab	FDA
Sensitivity (Supports)	dMMR	Colorectal Adenocarcinoma	Pembrolizumab	FDA
Sensitivity (Supports)	MSI-H	Colorectal Adenocarcinoma	Pembrolizumab	FDA
Sensitivity (Supports)	HER2-positive, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Pembrolizumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine, Oxaliplatin, Pembrolizumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-negative	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Pembrolizumab	FDA
Sensitivity (Supports)	HER2-negative	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine, Oxaliplatin, Pembrolizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 10	Adenocarcinoma of the Gastroesophageal Junction	Pembrolizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 10	Esophageal Adenocarcinoma	Pembrolizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Cisplatin, Paclitaxel, Pembrolizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Squamous Cell Carcinoma	Cisplatin, Paclitaxel, Pembrolizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Bevacizumab, Cisplatin, Paclitaxel, Pembrolizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Squamous Cell Carcinoma	Bevacizumab, Cisplatin, Paclitaxel, Pembrolizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Carboplatin, Paclitaxel, Pembrolizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Squamous Cell Carcinoma	Carboplatin, Paclitaxel, Pembrolizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Squamous Cell Carcinoma	Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Pembrolizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Squamous Cell Carcinoma	Pembrolizumab	FDA
Sensitivity (Supports)	MSI-L	Endometrial Carcinoma	Lenvatinib, Pembrolizumab	FDA
Sensitivity (Supports)	pMMR	Endometrial Carcinoma	Pembrolizumab	FDA
Sensitivity (Supports)	MSI-H	Endometrial Carcinoma	Pembrolizumab	FDA
Sensitivity (Supports)	TMB-H (>= 10 mutations / Mb)	Any solid tumor	Pembrolizumab	FDA
Sensitivity (Supports)	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Pembrolizumab	FDA
Sensitivity (Supports)	ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative	Invasive Breast Carcinoma	Paclitaxel, Pembrolizumab	FDA
Sensitivity (Supports)	ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative	Invasive Breast Carcinoma	Carboplatin, Gemcitabine, Pembrolizumab	FDA
Sensitivity (Supports)	FGFR2::v	Cholangiocarcinoma	Pemigatinib	FDA
Sensitivity (Supports)	FGFR2 rearrangements	Cholangiocarcinoma	Pemigatinib	FDA
Sensitivity (Supports)	FGFR1 rearrangements	Myeloid/Lymphoid Neoplasms	Pemigatinib	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Doxorubicin, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Doxorubicin, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	BCR::ABL1	Acute Lymphoid Leukemia	Cytarabine, Dexamethasone, Methotrexate, Ponatinib, Prednisone, Vincristine	FDA
Sensitivity (Supports)	ABL1 p.T315I, BCR::ABL1	Acute Lymphoid Leukemia	Ponatinib	FDA
Sensitivity (Supports)	ABL1 p.T315I	Chronic Myelogenous Leukemia	Ponatinib	FDA
Sensitivity (Supports)	v::RET	Non-Small Cell Lung Cancer	Pralsetinib	FDA
Sensitivity (Supports)	v::RET	Papillary Thyroid Cancer	Pralsetinib	FDA
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Erlotinib, Ramucirumab	FDA
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Erlotinib, Ramucirumab	FDA
Sensitivity (Supports)	v::ROS1	Non-Small Cell Lung Cancer	Repotrectinib	FDA
Sensitivity (Supports)	v::NTRK1	Any solid tumor	Repotrectinib	FDA
Sensitivity (Supports)	v::NTRK2	Any solid tumor	Repotrectinib	FDA
Sensitivity (Supports)	v::NTRK3	Any solid tumor	Repotrectinib	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Anastrozole, Ribociclib	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Anastrozole, Ribociclib	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Anastrozole, Ribociclib	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Letrozole, Ribociclib	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Ribociclib	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Ribociclib	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant, Ribociclib	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Ribociclib	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Ribociclib	FDA
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Rituximab	FDA
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Prednisolone, Rituximab, Vincristine	FDA
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine	FDA
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Fludarabine, Mitoxantrone, Rituximab	FDA
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine	FDA
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine	FDA
Sensitivity (Supports)	CD20 +	Diffuse Large B-Cell Lymphoma	Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine	FDA
Sensitivity (Supports)	CD20 +	Burkitt Lymphoma	Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine	FDA
Sensitivity (Supports)	CD20 +	Mature B-Cell Neoplasms	Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine	FDA
Sensitivity (Supports)	CD20 +	Chronic Lymphocytic Leukemia	Cyclophosphamide, Fludarabine, Rituximab	FDA
Sensitivity (Supports)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Rucaparib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Rucaparib	FDA
Sensitivity (Supports)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Rucaparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Rucaparib	FDA
Sensitivity (Supports)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Rucaparib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Rucaparib	FDA
Sensitivity (Supports)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Rucaparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Rucaparib	FDA
Sensitivity (Supports)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Rucaparib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Rucaparib	FDA
Sensitivity (Supports)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Rucaparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Rucaparib	FDA
Sensitivity (Supports)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Rucaparib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Rucaparib	FDA
Sensitivity (Supports)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Rucaparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Rucaparib	FDA
Sensitivity (Supports)	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Sacituzumab govitecan	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Sacituzumab govitecan	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Sacituzumab govitecan	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Sacituzumab govitecan	FDA
Sensitivity (Supports)	v::RET	Non-Small Cell Lung Cancer	Selpercatinib	FDA
Sensitivity (Supports)	RET oncogenic variants	Medullary Thyroid Cancer	Selpercatinib	FDA
Sensitivity (Supports)	v::RET	Anaplastic Thyroid Cancer	Selpercatinib	FDA
Sensitivity (Supports)	v::RET	Any solid tumor	Selpercatinib	FDA
Sensitivity (Supports)	KRAS p.G12C	Non-Small Cell Lung Cancer	Sotorasib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Talazoparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Talazoparib	FDA
Sensitivity (Supports)	MET Exon 14 (Splice Site)	Non-Small Cell Lung Cancer	Tepotinib	FDA
Sensitivity (Supports)	MET Exon 14 (Deletion)	Non-Small Cell Lung Cancer	Tepotinib	FDA
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Trametinib	FDA
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Trametinib	FDA
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib	FDA
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib	FDA
Sensitivity (Supports)	BRAF p.V600E	Non-Small Cell Lung Cancer	Dabrafenib, Trametinib	FDA
Sensitivity (Supports)	BRAF p.V600E	Anaplastic Thyroid Cancer	Dabrafenib, Trametinib	FDA
Sensitivity (Supports)	BRAF p.V600E	Any solid tumor	Dabrafenib, Trametinib	FDA
Sensitivity (Supports)	BRAF p.V600E	Low-Grade Glioma, NOS	Dabrafenib, Trametinib	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Gastrointestinal Stromal Tumor	Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab deruxtecan	FDA
Sensitivity (Supports)	HER2-low	Invasive Breast Carcinoma	Trastuzumab deruxtecan	FDA
Sensitivity (Supports)	ERBB2 activating variants	Non-Small Cell Lung Cancer	Trastuzumab deruxtecan	FDA
Sensitivity (Supports)	HER2-positive	Adenocarcinoma of the Gastroesophageal Junction	Trastuzumab deruxtecan	FDA
Sensitivity (Supports)	HER2-positive	Any solid tumor	Trastuzumab deruxtecan	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Capecitabine, Trastuzumab, Tucatinib	FDA
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Vemurafenib	FDA
Sensitivity (Supports)	BRAF p.V600E	Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease	Vemurafenib	FDA
Sensitivity (Supports)	BRAF p.V600K	Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease	Vemurafenib	FDA
Sensitivity (Supports)	EZH2 p.Y646N	Follicular Lymphoma	Tazemetostat	FDA
Sensitivity (Supports)	EZH2 p.Y646F	Follicular Lymphoma	Tazemetostat	FDA
Sensitivity (Supports)	EZH2 p.Y646H	Follicular Lymphoma	Tazemetostat	FDA
Sensitivity (Supports)	EZH2 p.Y646S	Follicular Lymphoma	Tazemetostat	FDA
Sensitivity (Supports)	EZH2 p.Y646C	Follicular Lymphoma	Tazemetostat	FDA
Sensitivity (Supports)	EZH2 p.A682G	Follicular Lymphoma	Tazemetostat	FDA
Sensitivity (Supports)	EZH2 p.A692V	Follicular Lymphoma	Tazemetostat	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	ATM pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	ATM oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	ATR oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	CDK12 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	ATR pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	FANCA oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	CHEK2 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	CHEK2 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	FANCA pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	MLH1 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	PALB2 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	PALB2 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	MLH1 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	MRE11 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	RAD51C pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	RAD51C oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	MRE11 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	NBN oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	NBN pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	TSC1 oncogenic variants	Renal Angiomyolipoma	Everolimus	FDA
Sensitivity (Supports)	TSC2 oncogenic variants	Renal Angiomyolipoma	Everolimus	FDA
Sensitivity (Supports)	TSC1 oncogenic variants	Subependymal Giant Cell Astrocytoma	Everolimus	FDA
Sensitivity (Supports)	TSC2 oncogenic variants	Subependymal Giant Cell Astrocytoma	Everolimus	FDA
Sensitivity (Supports)	CDK12 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Osimertinib	FDA
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Osimertinib	FDA
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib	FDA
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib	FDA
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib	FDA
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib	FDA
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Amivantamab, Carboplatin, Pemetrexed	FDA
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Amivantamab, Carboplatin, Pemetrexed	FDA
Sensitivity (Supports)	FOLR1 positive	Ovarian Epithelial Tumor	Mirvetuximab soravtansine	FDA
Sensitivity (Supports)	FOLR1 positive	High-Grade Serous Fallopian Tube Cancer	Mirvetuximab soravtansine	FDA
Sensitivity (Supports)	FOLR1 positive	Peritoneal Serous Carcinoma	Mirvetuximab soravtansine	FDA
Sensitivity (Supports)	BRAF rearrangements	Low-Grade Glioma, NOS	Tovorafenib	FDA
Sensitivity (Supports)	v::BRAF	Low-Grade Glioma, NOS	Tovorafenib	FDA
Sensitivity (Supports)	BRAF p.V600E	Low-Grade Glioma, NOS	Tovorafenib	FDA
Sensitivity (Supports)	BRAF p.V600K	Low-Grade Glioma, NOS	Tovorafenib	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Paclitaxel	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Gemcitabine	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Pemetrexed	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Pemetrexed	FDA
Sensitivity (Supports)	KRAS p.G12C	Colorectal Adenocarcinoma	Adagrasib, Cetuximab	FDA
Sensitivity (Supports)	IDH1 p.R132C	Astrocytoma	Vorasidenib	FDA
Sensitivity (Supports)	IDH1 p.R132G	Astrocytoma	Vorasidenib	FDA
Sensitivity (Supports)	IDH1 p.R132H	Astrocytoma	Vorasidenib	FDA
Sensitivity (Supports)	IDH1 p.R132L	Astrocytoma	Vorasidenib	FDA
Sensitivity (Supports)	IDH1 p.R132S	Astrocytoma	Vorasidenib	FDA
Sensitivity (Supports)	IDH2 p.R172K	Astrocytoma	Vorasidenib	FDA
Sensitivity (Supports)	IDH2 p.R172M	Astrocytoma	Vorasidenib	FDA
Sensitivity (Supports)	IDH2 p.R172G	Astrocytoma	Vorasidenib	FDA
Sensitivity (Supports)	IDH2 p.R172S	Astrocytoma	Vorasidenib	FDA
Sensitivity (Supports)	IDH2 p.R172W	Astrocytoma	Vorasidenib	FDA
Sensitivity (Supports)	IDH1 p.R132C	Oligodendroglioma	Vorasidenib	FDA
Sensitivity (Supports)	IDH1 p.R132G	Oligodendroglioma	Vorasidenib	FDA
Sensitivity (Supports)	IDH1 p.R132H	Oligodendroglioma	Vorasidenib	FDA
Sensitivity (Supports)	IDH1 p.R132L	Oligodendroglioma	Vorasidenib	FDA
Sensitivity (Supports)	IDH1 p.R132S	Oligodendroglioma	Vorasidenib	FDA
Sensitivity (Supports)	IDH2 p.R172K	Oligodendroglioma	Vorasidenib	FDA
Sensitivity (Supports)	IDH2 p.R172M	Oligodendroglioma	Vorasidenib	FDA
Sensitivity (Supports)	IDH2 p.R172G	Oligodendroglioma	Vorasidenib	FDA
Sensitivity (Supports)	IDH2 p.R172S	Oligodendroglioma	Vorasidenib	FDA
Sensitivity (Supports)	IDH2 p.R172W	Oligodendroglioma	Vorasidenib	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Anastrozole, Goserelin, Ribociclib	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Anastrozole, Goserelin, Ribociclib	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Anastrozole, Goserelin, Ribociclib	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Goserelin, Letrozole, Ribociclib	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Goserelin, Letrozole, Ribociclib	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Goserelin, Letrozole, Ribociclib	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Nivolumab, Pemetrexed	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Gemcitabine, Nivolumab	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Pemetrexed	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Ipilimumab, Nivolumab, Pemetrexed	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Paclitaxel	FDA
Sensitivity (Supports)	dMMR	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab	FDA
Sensitivity (Supports)	MSI-H	Colorectal Adenocarcinoma	Nivolumab	FDA
Sensitivity (Supports)	dMMR	Colorectal Adenocarcinoma	Nivolumab	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PIK3CA Somatic variants	Invasive Breast Carcinoma	Fulvestrant, Inavolisib, Palbociclib	FDA
Sensitivity (Supports)	HER2-negative, PIK3CA Somatic variants, PR positive	Invasive Breast Carcinoma	Fulvestrant, Inavolisib, Palbociclib	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PIK3CA Somatic variants, PR positive	Invasive Breast Carcinoma	Fulvestrant, Inavolisib, Palbociclib	FDA
Sensitivity (Supports)	CLDN18.2 >= 75%, HER2-negative	Adenocarcinoma of the Gastroesophageal Junction	Fluorouracil, Oxaliplatin, Zolbetuximab	FDA
Sensitivity (Supports)	CLDN18.2 >= 75%, HER2-negative	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine, Oxaliplatin, Zolbetuximab	FDA
Sensitivity (Supports)	HER2-positive	Intraductal Papillary Neoplasm of the Bile Duct	Zanidatamab	FDA
Sensitivity (Supports)	HER2-positive	Intracholecystic Papillary Neoplasm	Zanidatamab	FDA
Sensitivity (Supports)	HER2-positive	Cholangiocarcinoma	Zanidatamab	FDA
Sensitivity (Supports)	v::NRG1	Non-Small Cell Lung Cancer	Zenocutuzumab	FDA
Sensitivity (Supports)	v::NRG1	Pancreatic Adenocarcinoma	Zenocutuzumab	FDA
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Ensartinib	FDA
Sensitivity (Supports)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib, Fluorouracil, Oxaliplatin	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Asciminib	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Asciminib	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Pemetrexed, Tremelimumab	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Pemetrexed, Tremelimumab	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Gemcitabine, Tremelimumab	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Gemcitabine, Tremelimumab	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Nab-paclitaxel, Tremelimumab	FDA
Sensitivity (Supports)	t(KMT2A;v)	Acute Lymphoid Leukemia	Revumenib	FDA
Sensitivity (Supports)	t(KMT2A;v)	Acute Myeloid Leukemia	Revumenib	FDA
Sensitivity (Supports)	t(KMT2A;v)	Burkitt Lymphoma	Revumenib	FDA
Sensitivity (Supports)	t(KMT2A;v)	Acute Leukemias of Ambiguous Lineage	Revumenib	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Anastrozole	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Exemestane	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Exemestane	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Exemestane	FDA
Sensitivity (Supports)	MSI-H	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab	FDA
Sensitivity (Supports)	v::ROS1	Non-Small Cell Lung Cancer	Taletrectinib	FDA
Sensitivity (Supports)	c-Met >= 50%	Lung Non-Squamous Non-Small Cell Carcinoma	Telisotuzumab Vedotin	FDA
Sensitivity (Supports)	KRAS p.G12C	Low-Grade Serous Ovarian Cancer	Avutometinib, Defactinib	FDA
Sensitivity (Supports)	KRAS p.G12V	Low-Grade Serous Ovarian Cancer	Avutometinib, Defactinib	FDA
Sensitivity (Supports)	t(15;17)	APL with PML-RARA	Arsenic trioxide	FDA
Sensitivity (Supports)	t(15;17)	APL with PML-RARA	Arsenic trioxide	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Nilotinib	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Nilotinib	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Asciminib	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Head and Neck Squamous Cell Carcinoma	Pembrolizumab	FDA
Sensitivity (Supports)	EGFR Somatic variants	Non-Small Cell Lung Cancer	Datopotamab deruxtecan	FDA
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Datopotamab deruxtecan	FDA
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Datopotamab deruxtecan	FDA
Sensitivity (Supports)	EGFR p.T790M	Non-Small Cell Lung Cancer	Datopotamab deruxtecan	FDA
Sensitivity (Supports)	EGFR Exon 20 (Insertion)	Invasive Breast Carcinoma	Datopotamab deruxtecan	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Datopotamab deruxtecan	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Non-Small Cell Lung Cancer	Datopotamab deruxtecan	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Datopotamab deruxtecan	FDA
Sensitivity (Supports)	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Sunvozertinib	FDA
Sensitivity (Supports)	ERBB2 TKD activating variants	Lung Non-Squamous Non-Small Cell Carcinoma	Zongertinib	FDA
Sensitivity (Supports)	CD30 +	Hodgkin Lymphoma	Brentuximab vedotin, Dacarbazine, Doxorubicin, Vinblastine	EMA
Sensitivity (Supports)	CD30 +	Hodgkin Lymphoma	Brentuximab vedotin	EMA
Sensitivity (Supports)	CD30 +	Hodgkin Lymphoma	Brentuximab vedotin	EMA
Sensitivity (Supports)	CD30 +	Cutaneous T-cell Lymphoma	Brentuximab vedotin	EMA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Everolimus, Exemestane	EMA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Everolimus, Exemestane	EMA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Everolimus, Exemestane	EMA
Sensitivity (Supports)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisolone	EMA
Sensitivity (Supports)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisolone	EMA
Sensitivity (Supports)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisolone	EMA
Sensitivity (Supports)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisolone	EMA
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Alectinib	EMA
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Alectinib	EMA
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Alectinib	EMA
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Brigatinib	EMA
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Brigatinib	EMA
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Bevacizumab, Erlotinib	EMA
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Bevacizumab, Erlotinib	EMA
Sensitivity (Supports)	PDGFRA p.D842V	Gastrointestinal Stromal Tumor	Avapritinib	EMA
Sensitivity (Supports)	CD22 +, not BCR::ABL1	Acute Lymphoid Leukemia	Inotuzumab ozogamicin	EMA
Sensitivity (Supports)	CD22 +	Acute Lymphoid Leukemia	Inotuzumab ozogamicin	EMA
Sensitivity (Supports)	CD19 +	Acute Lymphoid Leukemia	Blinatumomab	EMA
Sensitivity (Supports)	CD19 +, not BCR::ABL1	Acute Lymphoid Leukemia	Blinatumomab	EMA
Sensitivity (Supports)	CD19 +, not BCR::ABL1	Acute Lymphoid Leukemia	Blinatumomab	EMA
Sensitivity (Supports)	CD19 +, not BCR::ABL1	Acute Lymphoid Leukemia	Blinatumomab	EMA
Sensitivity (Supports)	CD19 +, not BCR::ABL1	Acute Lymphoid Leukemia	Blinatumomab	EMA
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Bosutinib	EMA
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Bosutinib	EMA
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Binimetinib, Encorafenib	EMA
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Binimetinib, Encorafenib	EMA
Sensitivity (Supports)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib	EMA
Sensitivity (Supports)	BRAF p.V600E	Non-Small Cell Lung Cancer	Binimetinib, Encorafenib	EMA
Sensitivity (Supports)	v::RET	Medullary Thyroid Cancer	Vandetanib	EMA
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Cobimetinib, Vemurafenib	EMA
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Cobimetinib, Vemurafenib	EMA
Sensitivity (Supports)	EGFR activating variants	Non-Small Cell Lung Cancer	Erlotinib, Ramucirumab	EMA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Trastuzumab	EMA
Sensitivity (Supports)	ERBB2 amplification	Invasive Breast Carcinoma	Docetaxel, Trastuzumab	EMA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab deruxtecan	EMA
Sensitivity (Supports)	HER2-low	Invasive Breast Carcinoma	Trastuzumab deruxtecan	EMA
Sensitivity (Supports)	ERBB2 amplification	Non-Small Cell Lung Cancer	Trastuzumab deruxtecan	EMA
Sensitivity (Supports)	ERBB2 activating variants	Non-Small Cell Lung Cancer	Trastuzumab deruxtecan	EMA
Sensitivity (Supports)	HER2-positive	Adenocarcinoma of the Gastroesophageal Junction	Trastuzumab deruxtecan	EMA
Sensitivity (Supports)	ERBB2 amplification	Adenocarcinoma of the Gastroesophageal Junction	Trastuzumab deruxtecan	EMA
Sensitivity (Supports)	EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Cetuximab	EMA
Sensitivity (Supports)	EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Cetuximab, Irinotecan	EMA
Sensitivity (Supports)	EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Cetuximab, Fluorouracil, Oxaliplatin	EMA
Sensitivity (Supports)	ER positive	Invasive Breast Carcinoma	Fulvestrant	EMA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant, Palbociclib	EMA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Palbociclib	EMA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Palbociclib	EMA
Sensitivity (Supports)	EGFR TKD activating variants	Non-Small Cell Lung Cancer	Gefitinib	EMA
Sensitivity (Supports)	EGFR activating variants	Non-Small Cell Lung Cancer	Afatinib	EMA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab	EMA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Paclitaxel, Trastuzumab	EMA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Trastuzumab	EMA
Sensitivity (Supports)	ER positive, HER2-positive, PR positive	Invasive Breast Carcinoma	Anastrozole, Trastuzumab	EMA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab	EMA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Paclitaxel, Trastuzumab	EMA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Trastuzumab	EMA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Trastuzumab	EMA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Doxorubicin, Paclitaxel, Trastuzumab	EMA
Sensitivity (Supports)	ERBB2 amplification	Invasive Breast Carcinoma	Trastuzumab	EMA
Sensitivity (Supports)	ERBB2 amplification	Invasive Breast Carcinoma	Paclitaxel, Trastuzumab	EMA
Sensitivity (Supports)	ERBB2 amplification	Invasive Breast Carcinoma	Docetaxel, Trastuzumab	EMA
Sensitivity (Supports)	ER positive, HER2-positive	Invasive Breast Carcinoma	Anastrozole, Trastuzumab	EMA
Sensitivity (Supports)	ERBB2 amplification	Invasive Breast Carcinoma	Trastuzumab	EMA
Sensitivity (Supports)	ERBB2 amplification	Invasive Breast Carcinoma	Paclitaxel, Trastuzumab	EMA
Sensitivity (Supports)	ERBB2 amplification	Invasive Breast Carcinoma	Docetaxel, Trastuzumab	EMA
Sensitivity (Supports)	ERBB2 amplification	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Trastuzumab	EMA
Sensitivity (Supports)	ERBB2 amplification	Invasive Breast Carcinoma	Doxorubicin, Paclitaxel, Trastuzumab	EMA
Sensitivity (Supports)	HER2-positive	Esophagogastric Adenocarcinoma	Capecitabine, Cisplatin, Trastuzumab	EMA
Sensitivity (Supports)	HER2-positive	Esophagogastric Adenocarcinoma	Cisplatin, Fluorouracil, Trastuzumab	EMA
Sensitivity (Supports)	ERBB2 amplification	Esophagogastric Adenocarcinoma	Capecitabine, Cisplatin, Trastuzumab	EMA
Sensitivity (Supports)	ERBB2 amplification	Esophagogastric Adenocarcinoma	Cisplatin, Fluorouracil, Trastuzumab	EMA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Letrozole, Palbociclib	EMA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Palbociclib	EMA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Palbociclib	EMA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant, Palbociclib	EMA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Palbociclib	EMA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Palbociclib	EMA
Sensitivity (Supports)	not BCR::ABL1	Chronic Myelogenous Leukemia	Imatinib	EMA
Sensitivity (Supports)	not BCR::ABL1	Chronic Myelogenous Leukemia	Imatinib	EMA
Sensitivity (Supports)	not BCR::ABL1	Acute Lymphoid Leukemia	Imatinib	EMA
Sensitivity (Supports)	not BCR::ABL1	Acute Lymphoid Leukemia	Imatinib	EMA
Sensitivity (Supports)	PDGFRA rearrangements	Myelodysplastic Syndromes	Imatinib	EMA
Sensitivity (Supports)	PDGFRB rearrangements	Myelodysplastic Syndromes	Imatinib	EMA
Sensitivity (Supports)	PDGFRA rearrangements	Myeloproliferative Neoplasm	Imatinib	EMA
Sensitivity (Supports)	PDGFRB rearrangements	Myeloproliferative Neoplasm	Imatinib	EMA
Sensitivity (Supports)	FIP1L1::PDGFRA	Chronic Eosinophilic Leukemia, NOS	Imatinib	EMA
Sensitivity (Supports)	CD117 +	Gastrointestinal Stromal Tumor	Imatinib	EMA
Sensitivity (Supports)	CD117 +	Gastrointestinal Stromal Tumor	Imatinib	EMA
Sensitivity (Supports)	ABL1 p.T315I	Chronic Myelogenous Leukemia	Ponatinib	EMA
Sensitivity (Supports)	not BCR::ABL1	Acute Lymphoid Leukemia	Ponatinib	EMA
Sensitivity (Supports)	ABL1 p.T315I, not BCR::ABL1	Acute Lymphoid Leukemia	Ponatinib	EMA
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Durvalumab	EMA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Tremelimumab	EMA
Sensitivity (Supports)	dMMR	Endometrial Carcinoma	Carboplatin, Durvalumab, Paclitaxel	EMA
Sensitivity (Supports)	pMMR	Endometrial Carcinoma	Carboplatin, Durvalumab, Olaparib, Paclitaxel	EMA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Tremelimumab	EMA
Sensitivity (Supports)	MSI-H	Endometrial Carcinoma	Dostarlimab	EMA
Sensitivity (Supports)	dMMR	Endometrial Carcinoma	Dostarlimab	EMA
Sensitivity (Supports)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Pembrolizumab	EMA
Sensitivity (Supports)	CD274 amplification, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Pembrolizumab	EMA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Pembrolizumab, Pemetrexed	EMA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Pembrolizumab, Pemetrexed	EMA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Gemcitabine, Pembrolizumab	EMA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Gemcitabine, Pembrolizumab	EMA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Paclitaxel, Pembrolizumab	EMA
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Pembrolizumab	EMA
Sensitivity (Supports)	PD-L1 (CPS) >= 10	Bladder Urothelial Carcinoma	Pembrolizumab	EMA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Head and Neck Squamous Cell Carcinoma	Pembrolizumab	EMA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Head and Neck Squamous Cell Carcinoma	Carboplatin, Fluorouracil, Pembrolizumab	EMA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Head and Neck Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Pembrolizumab	EMA
Sensitivity (Supports)	PD-L1 >= 50%	Head and Neck Squamous Cell Carcinoma	Pembrolizumab	EMA
Sensitivity (Supports)	MSI-H	Colorectal Adenocarcinoma	Pembrolizumab	EMA
Sensitivity (Supports)	dMMR	Colorectal Adenocarcinoma	Pembrolizumab	EMA
Sensitivity (Supports)	MSI-H	Endometrial Carcinoma	Pembrolizumab	EMA
Sensitivity (Supports)	dMMR	Endometrial Carcinoma	Pembrolizumab	EMA
Sensitivity (Supports)	MSI-H	Esophagogastric Adenocarcinoma	Pembrolizumab	EMA
Sensitivity (Supports)	dMMR	Esophagogastric Adenocarcinoma	Pembrolizumab	EMA
Sensitivity (Supports)	MSI-H	Gastrointestinal Stromal Tumor	Pembrolizumab	EMA
Sensitivity (Supports)	dMMR	Gastrointestinal Stromal Tumor	Pembrolizumab	EMA
Sensitivity (Supports)	MSI-H	Cholangiocarcinoma	Pembrolizumab	EMA
Sensitivity (Supports)	dMMR	Cholangiocarcinoma	Pembrolizumab	EMA
Sensitivity (Supports)	PD-L1 (CPS) >= 10	Esophageal Adenocarcinoma	Cisplatin, Fluorouracil, Pembrolizumab	EMA
Sensitivity (Supports)	PD-L1 (CPS) >= 10	Esophageal Adenocarcinoma	Carboplatin, Fluorouracil, Pembrolizumab	EMA
Sensitivity (Supports)	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Pembrolizumab	EMA
Sensitivity (Supports)	ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative	Invasive Breast Carcinoma	Paclitaxel, Pembrolizumab	EMA
Sensitivity (Supports)	ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative	Invasive Breast Carcinoma	Nab-paclitaxel, Pembrolizumab	EMA
Sensitivity (Supports)	ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative	Invasive Breast Carcinoma	Carboplatin, Gemcitabine, Pembrolizumab	EMA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Carboplatin, Paclitaxel, Pembrolizumab	EMA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab	EMA
Sensitivity (Supports)	HER2-positive, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Pembrolizumab, Trastuzumab	EMA
Sensitivity (Supports)	HER2-positive, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Carboplatin, Fluorouracil, Pembrolizumab, Trastuzumab	EMA
Sensitivity (Supports)	HER2-negative, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Pembrolizumab	EMA
Sensitivity (Supports)	HER2-negative, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Carboplatin, Fluorouracil, Pembrolizumab	EMA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab emtansine	EMA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab emtansine	EMA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Letrozole, Ribociclib	EMA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Ribociclib	EMA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Ribociclib	EMA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant, Ribociclib	EMA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Ribociclib	EMA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Ribociclib	EMA
Sensitivity (Supports)	KRAS p.G12C	Non-Small Cell Lung Cancer	Adagrasib	EMA
Sensitivity (Supports)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR, Wild type ROS1	Non-Small Cell Lung Cancer	Cemiplimab	EMA
Sensitivity (Supports)	PD-L1 >= 1%, Wild type ALK, Wild type EGFR, Wild type ROS1	Non-Small Cell Lung Cancer	Carboplatin, Cemiplimab, Pemetrexed	EMA
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Lorlatinib	EMA
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Lorlatinib	EMA
Sensitivity (Supports)	KRAS p.G12C	Non-Small Cell Lung Cancer	Sotorasib	EMA
Sensitivity (Supports)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Olaparib	EMA
Sensitivity (Supports)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	EMA
Sensitivity (Supports)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib	EMA
Sensitivity (Supports)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Olaparib	EMA
Sensitivity (Supports)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	EMA
Sensitivity (Supports)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib	EMA
Sensitivity (Supports)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Olaparib	EMA
Sensitivity (Supports)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	EMA
Sensitivity (Supports)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib	EMA
Sensitivity (Supports)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Olaparib	EMA
Sensitivity (Supports)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	EMA
Sensitivity (Supports)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib	EMA
Sensitivity (Supports)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib	EMA
Sensitivity (Supports)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib	EMA
Sensitivity (Supports)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib	EMA
Sensitivity (Supports)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib	EMA
Sensitivity (Supports)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib	EMA
Sensitivity (Supports)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib	EMA
Sensitivity (Supports)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib	EMA
Sensitivity (Supports)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib	EMA
Sensitivity (Supports)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib	EMA
Sensitivity (Supports)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib	EMA
Sensitivity (Supports)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib	EMA
Sensitivity (Supports)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib	EMA
Sensitivity (Supports)	HRD	Ovarian Epithelial Tumor	Bevacizumab, Olaparib	EMA
Sensitivity (Supports)	HRD	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib	EMA
Sensitivity (Supports)	HRD	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib	EMA
Sensitivity (Supports)	BRCA1 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib	EMA
Sensitivity (Supports)	BRCA1 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib	EMA
Sensitivity (Supports)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib	EMA
Sensitivity (Supports)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib	EMA
Sensitivity (Supports)	BRCA1 pathogenic variants	Pancreatic Adenocarcinoma	Olaparib	EMA
Sensitivity (Supports)	BRCA2 pathogenic variants	Pancreatic Adenocarcinoma	Olaparib	EMA
Sensitivity (Supports)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Olaparib	EMA
Sensitivity (Supports)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Olaparib	EMA
Sensitivity (Supports)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Olaparib	EMA
Sensitivity (Supports)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Olaparib	EMA
Sensitivity (Supports)	pMMR	Endometrial Carcinoma	Durvalumab, Olaparib	EMA
Sensitivity (Supports)	FGFR2::v	Cholangiocarcinoma	Futibatinib	EMA
Sensitivity (Supports)	FGFR2 rearrangements	Cholangiocarcinoma	Futibatinib	EMA
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine	EMA
Sensitivity (Supports)	CD20 +	Diffuse Large B-Cell Lymphoma	Corticosteroid, Cyclophosphamide, Cytarabine, Doxorubicin, Etoposide, Methotrexate, Rituximab, Vincristine	EMA
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Corticosteroid, Cyclophosphamide, Cytarabine, Doxorubicin, Etoposide, Methotrexate, Rituximab, Vincristine	EMA
Sensitivity (Supports)	CD20 +	Burkitt Lymphoma	Corticosteroid, Cyclophosphamide, Cytarabine, Doxorubicin, Etoposide, Methotrexate, Rituximab, Vincristine	EMA
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Trametinib	EMA
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Trametinib	EMA
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib	EMA
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib	EMA
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib	EMA
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib	EMA
Sensitivity (Supports)	BRAF p.V600E	Non-Small Cell Lung Cancer	Dabrafenib, Trametinib	EMA
Sensitivity (Supports)	BRAF p.V600K	Non-Small Cell Lung Cancer	Dabrafenib, Trametinib	EMA
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Binimetinib, Encorafenib	EMA
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Binimetinib, Encorafenib	EMA
Sensitivity (Supports)	BRAF p.V600E	Non-Small Cell Lung Cancer	Binimetinib, Encorafenib	EMA
Sensitivity (Supports)	CD33 +	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Gemtuzumab ozogamicin	EMA
Sensitivity (Supports)	ER positive, HER2-positive, PR positive	Invasive Breast Carcinoma	Neratinib	EMA
Sensitivity (Supports)	ER positive, HER2-positive	Invasive Breast Carcinoma	Neratinib	EMA
Sensitivity (Supports)	HER2-positive, PR positive	Invasive Breast Carcinoma	Neratinib	EMA
Sensitivity (Supports)	ER positive, ERBB2 amplification, PR positive	Invasive Breast Carcinoma	Neratinib	EMA
Sensitivity (Supports)	ER positive, ERBB2 amplification	Invasive Breast Carcinoma	Neratinib	EMA
Sensitivity (Supports)	ERBB2 amplification, PR positive	Invasive Breast Carcinoma	Neratinib	EMA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Pemetrexed	EMA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Ipilimumab, Nivolumab, Pemetrexed	EMA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Paclitaxel	EMA
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Carboplatin, Nivolumab, Paclitaxel	EMA
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Carboplatin, Nivolumab, Pemetrexed	EMA
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Cisplatin, Gemcitabine, Nivolumab	EMA
Sensitivity (Supports)	PD-L1 >= 1%	Bladder Urothelial Carcinoma	Nivolumab	EMA
Sensitivity (Supports)	MSI-H	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab	EMA
Sensitivity (Supports)	dMMR	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab	EMA
Sensitivity (Supports)	PD-L1 >= 1%	Esophageal Squamous Cell Carcinoma	Ipilimumab, Nivolumab	EMA
Sensitivity (Supports)	PD-L1 >= 1%	Esophageal Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Nivolumab	EMA
Sensitivity (Supports)	HER2-negative, PD-L1 (CPS) >= 5	Esophageal Adenocarcinoma	Fluorouracil, Nivolumab, Oxaliplatin	EMA
Sensitivity (Supports)	HER2-negative, PD-L1 (CPS) >= 5	Adenocarcinoma of the Gastroesophageal Junction	Fluorouracil, Nivolumab, Oxaliplatin	EMA
Sensitivity (Supports)	HER2-negative, PD-L1 (CPS) >= 5	Stomach Adenocarcinoma	Capecitabine, Nivolumab, Oxaliplatin	EMA
Sensitivity (Supports)	HER2-negative, PD-L1 (CPS) >= 5	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine, Nivolumab, Oxaliplatin	EMA
Sensitivity (Supports)	HER2-negative, PD-L1 (CPS) >= 5	Esophageal Adenocarcinoma	Capecitabine, Nivolumab, Oxaliplatin	EMA
Sensitivity (Supports)	HER2-negative, PD-L1 (CPS) >= 5	Stomach Adenocarcinoma	Fluorouracil, Nivolumab, Oxaliplatin	EMA
Sensitivity (Supports)	PD-L1 < 1%	Melanoma	Nivolumab, Relatlimab	EMA
Sensitivity (Supports)	ER positive, ESR1 activating variants, HER2-negative	Invasive Breast Carcinoma	Elacestrant	EMA
Sensitivity (Supports)	FGFR2::v	Cholangiocarcinoma	Elacestrant	EMA
Sensitivity (Supports)	FGFR2 rearrangements	Cholangiocarcinoma	Elacestrant	EMA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab	EMA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab	EMA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab	EMA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab	EMA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab	EMA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab	EMA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Pertuzumab, Trastuzumab	EMA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab	EMA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab	EMA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab	EMA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab	EMA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab	EMA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab	EMA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab	EMA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab	EMA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab	EMA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Pertuzumab, Trastuzumab	EMA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab	EMA
Sensitivity (Supports)	ER positive, HER2-negative, PIK3CA Somatic variants	Invasive Breast Carcinoma	Alpelisib, Fulvestrant	EMA
Sensitivity (Supports)	HER2-negative, PIK3CA Somatic variants, PR positive	Invasive Breast Carcinoma	Alpelisib, Fulvestrant	EMA
Sensitivity (Supports)	ER positive, HER2-negative, PIK3CA Somatic variants, PR positive	Invasive Breast Carcinoma	Alpelisib, Fulvestrant	EMA
Sensitivity (Supports)	v::RET	Non-Small Cell Lung Cancer	Selpercatinib	EMA
Sensitivity (Supports)	v::RET	Papillary Thyroid Cancer	Selpercatinib	EMA
Sensitivity (Supports)	RET p.M918T	Medullary Thyroid Cancer	Selpercatinib	EMA
Sensitivity (Supports)	v::RET	Any solid tumor	Selpercatinib	EMA
Sensitivity (Supports)	5q deletion	Myeloproliferative Neoplasm	Lenalidomide	EMA
Sensitivity (Supports)	v::ROS1	Non-Small Cell Lung Cancer	Entrectinib	EMA
Sensitivity (Supports)	v::NTRK1	Any solid tumor	Entrectinib	EMA
Sensitivity (Supports)	v::NTRK2	Any solid tumor	Entrectinib	EMA
Sensitivity (Supports)	v::NTRK3	Any solid tumor	Entrectinib	EMA
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	EMA
Sensitivity (Supports)	not BCR::ABL1	Chronic Myelogenous Leukemia	Asciminib	EMA
Sensitivity (Supports)	BRAF p.V600E	Low-Grade Glioma, NOS	Dabrafenib, Trametinib	EMA
Sensitivity (Supports)	BRAF p.V600E	High-Grade Glioma, NOS	Dabrafenib, Trametinib	EMA
Sensitivity (Supports)	not BCR::ABL1	Chronic Myelogenous Leukemia	Dasatinib	EMA
Sensitivity (Supports)	not BCR::ABL1	Acute Lymphoid Leukemia	Dasatinib	EMA
Sensitivity (Supports)	not BCR::ABL1	Chronic Myelogenous Leukemia	Dasatinib	EMA
Sensitivity (Supports)	not BCR::ABL1	Chronic Myelogenous Leukemia	Dasatinib	EMA
Sensitivity (Supports)	not BCR::ABL1	Acute Lymphoid Leukemia	Dasatinib	EMA
Sensitivity (Supports)	MET Exon 14 (Splice Site)	Non-Small Cell Lung Cancer	Capmatinib	EMA
Sensitivity (Supports)	MET Exon 14 (Deletion)	Non-Small Cell Lung Cancer	Capmatinib	EMA
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Dabrafenib	EMA
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Dabrafenib	EMA
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib	EMA
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib	EMA
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib	EMA
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib	EMA
Sensitivity (Supports)	BRAF p.V600E	Non-Small Cell Lung Cancer	Dabrafenib, Trametinib	EMA
Sensitivity (Supports)	BRAF p.V600K	Non-Small Cell Lung Cancer	Dabrafenib, Trametinib	EMA
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Osimertinib	EMA
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Osimertinib	EMA
Sensitivity (Supports)	EGFR activating variants	Non-Small Cell Lung Cancer	Osimertinib	EMA
Sensitivity (Supports)	EGFR p.T790M	Non-Small Cell Lung Cancer	Osimertinib	EMA
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Cisplatin, Osimertinib	EMA
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Carboplatin, Osimertinib	EMA
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Cisplatin, Osimertinib	EMA
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Carboplatin, Osimertinib	EMA
Sensitivity (Supports)	BRCA1 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Talazoparib	EMA
Sensitivity (Supports)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Talazoparib	EMA
Sensitivity (Supports)	EGFR activating variants	Non-Small Cell Lung Cancer	Erlotinib	EMA
Sensitivity (Supports)	EGFR activating variants	Non-Small Cell Lung Cancer	Erlotinib	EMA
Sensitivity (Supports)	not BCR::ABL1	Chronic Myelogenous Leukemia	Nilotinib	EMA
Sensitivity (Supports)	not BCR::ABL1	Chronic Myelogenous Leukemia	Nilotinib	EMA
Sensitivity (Supports)	not BCR::ABL1	Chronic Myelogenous Leukemia	Nilotinib	EMA
Sensitivity (Supports)	PD-L1 >= 5%	Bladder Urothelial Carcinoma	Atezolizumab	EMA
Sensitivity (Supports)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab	EMA
Sensitivity (Supports)	EGFR Somatic variants	Non-Small Cell Lung Cancer	Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel	EMA
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel	EMA
Sensitivity (Supports)	Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab, Carboplatin, Nab-paclitaxel	EMA
Sensitivity (Supports)	Wild type ALK	Non-Small Cell Lung Cancer	Atezolizumab, Carboplatin, Nab-paclitaxel	EMA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab, Carboplatin, Nab-paclitaxel	EMA
Sensitivity (Supports)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab	EMA
Sensitivity (Supports)	PD-L1 >= 10% TIIC, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab	EMA
Sensitivity (Supports)	EGFR Somatic variants	Non-Small Cell Lung Cancer	Atezolizumab	EMA
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Atezolizumab	EMA
Sensitivity (Supports)	ER negative, HER2-negative, PD-L1 >= 1%, PR negative	Invasive Breast Carcinoma	Atezolizumab, Nab-paclitaxel	EMA
Sensitivity (Supports)	MET Exon 14 (Splice Site)	Non-Small Cell Lung Cancer	Tepotinib	EMA
Sensitivity (Supports)	MET Exon 14 (Deletion)	Non-Small Cell Lung Cancer	Tepotinib	EMA
Sensitivity (Supports)	IDH1 p.R132C	Acute Myeloid Leukemia	Azacitidine, Ivosidenib	EMA
Sensitivity (Supports)	IDH1 p.R132G	Acute Myeloid Leukemia	Azacitidine, Ivosidenib	EMA
Sensitivity (Supports)	IDH1 p.R132H	Acute Myeloid Leukemia	Azacitidine, Ivosidenib	EMA
Sensitivity (Supports)	IDH1 p.R132L	Acute Myeloid Leukemia	Azacitidine, Ivosidenib	EMA
Sensitivity (Supports)	IDH1 p.R132S	Acute Myeloid Leukemia	Azacitidine, Ivosidenib	EMA
Sensitivity (Supports)	IDH1 p.R132C	Cholangiocarcinoma	Ivosidenib	EMA
Sensitivity (Supports)	IDH1 p.R132G	Cholangiocarcinoma	Ivosidenib	EMA
Sensitivity (Supports)	IDH1 p.R132H	Cholangiocarcinoma	Ivosidenib	EMA
Sensitivity (Supports)	IDH1 p.R132L	Cholangiocarcinoma	Ivosidenib	EMA
Sensitivity (Supports)	IDH1 p.R132S	Cholangiocarcinoma	Ivosidenib	EMA
Sensitivity (Supports)	PML::RARA	APL with PML-RARA	Arsenic trioxide	EMA
Sensitivity (Supports)	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Sacituzumab govitecan	EMA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Sacituzumab govitecan	EMA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Sacituzumab govitecan	EMA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Sacituzumab govitecan	EMA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Capecitabine, Trastuzumab, Tucatinib	EMA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Capecitabine, Lapatinib	EMA
Sensitivity (Supports)	ER positive, HER2-positive, PR negative	Invasive Breast Carcinoma	Lapatinib, Trastuzumab	EMA
Sensitivity (Supports)	ER positive, HER2-positive, PR positive	Invasive Breast Carcinoma	Lapatinib, Letrozole	EMA
Sensitivity (Supports)	ERBB2 amplification	Invasive Breast Carcinoma	Capecitabine, Lapatinib	EMA
Sensitivity (Supports)	ER positive, ERBB2 amplification, PR negative	Invasive Breast Carcinoma	Lapatinib, Trastuzumab	EMA
Sensitivity (Supports)	ER positive, ERBB2 amplification, PR positive	Invasive Breast Carcinoma	Lapatinib, Letrozole	EMA
Sensitivity (Supports)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Fluorouracil, Oxaliplatin, Panitumumab	EMA
Sensitivity (Supports)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Fluorouracil, Irinotecan, Panitumumab	EMA
Sensitivity (Supports)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Fluorouracil, Irinotecan, Panitumumab	EMA
Sensitivity (Supports)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Panitumumab	EMA
Sensitivity (Supports)	TP53 Somatic variants	Chronic Lymphocytic Leukemia	Venetoclax	EMA
Sensitivity (Supports)	TP53 deletion	Chronic Lymphocytic Leukemia	Venetoclax	EMA
Sensitivity (Supports)	not 17p deletion	Chronic Lymphocytic Leukemia	Venetoclax	EMA
Sensitivity (Supports)	Wild type TP53	Chronic Lymphocytic Leukemia	Venetoclax	EMA
Sensitivity (Supports)	not 17p deletion	Chronic Lymphocytic Leukemia	Venetoclax	EMA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Anastrozole	EMA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole	EMA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole	EMA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Letrozole	EMA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole	EMA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole	EMA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant	EMA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant	EMA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant	EMA
Sensitivity (Supports)	v::NTRK1	Any solid tumor	Larotrectinib	EMA
Sensitivity (Supports)	v::NTRK2	Any solid tumor	Larotrectinib	EMA
Sensitivity (Supports)	v::NTRK3	Any solid tumor	Larotrectinib	EMA
Sensitivity (Supports)	EGFR activating variants	Non-Small Cell Lung Cancer	Dacomitinib	EMA
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Crizotinib	EMA
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Crizotinib	EMA
Sensitivity (Supports)	v::ROS1	Non-Small Cell Lung Cancer	Crizotinib	EMA
Sensitivity (Supports)	v::ALK	Anaplastic Large Cell Lymphoma	Crizotinib	EMA
Sensitivity (Supports)	v::ALK	Inflammatory Myofibroblastic Tumor	Crizotinib	EMA
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Gilteritinib	EMA
Sensitivity (Supports)	FLT3 p.D835Y	Acute Myeloid Leukemia	Gilteritinib	EMA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Pemetrexed	EMA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Ipilimumab, Nivolumab, Pemetrexed	EMA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Paclitaxel	EMA
Sensitivity (Supports)	MSI-H	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab	EMA
Sensitivity (Supports)	dMMR	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab	EMA
Sensitivity (Supports)	PD-L1 >= 1%	Esophageal Squamous Cell Carcinoma	Ipilimumab, Nivolumab	EMA
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Vemurafenib	EMA
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Vemurafenib	EMA
Sensitivity (Supports)	TP53 deletion	Chronic Lymphocytic Leukemia	Idelalisib, Rituximab	EMA
Sensitivity (Supports)	TP53 Somatic variants	Chronic Lymphocytic Leukemia	Idelalisib, Rituximab	EMA
Sensitivity (Supports)	not 17p deletion	Chronic Lymphocytic Leukemia	Idelalisib, Rituximab	EMA
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Ceritinib	EMA
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Ceritinib	EMA
Sensitivity (Supports)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Pemetrexed, Tislelizumab	EMA
Sensitivity (Supports)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Pemetrexed, Tislelizumab	EMA
Sensitivity (Supports)	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Amivantamab, Carboplatin, Pemetrexed	EMA
Sensitivity (Supports)	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Amivantamab	EMA
Sensitivity (Supports)	ER positive, HER2-negative, PIK3CA Somatic variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	EMA
Sensitivity (Supports)	ER positive, HER2-negative, PIK3CA amplification	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	EMA
Sensitivity (Supports)	AKT1 amplification, ER positive, HER2-negative	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	EMA
Sensitivity (Supports)	AKT1 Somatic variants, ER positive, HER2-negative	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	EMA
Sensitivity (Supports)	ER positive, HER2-negative, PTEN nonsense variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	EMA
Sensitivity (Supports)	ER positive, HER2-negative, PTEN frameshift variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	EMA
Sensitivity (Supports)	ER positive, HER2-negative, PTEN splice site variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	EMA
Sensitivity (Supports)	ER positive, HER2-negative, PTEN deletion	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	EMA
Sensitivity (Supports)	FGFR3::TACC3	Bladder Urothelial Carcinoma	Erdafitinib	EMA
Sensitivity (Supports)	FGFR3::BAIAP2L1	Bladder Urothelial Carcinoma	Erdafitinib	EMA
Sensitivity (Supports)	FGFR3 p.R248C	Bladder Urothelial Carcinoma	Erdafitinib	EMA
Sensitivity (Supports)	FGFR3 p.S249C	Bladder Urothelial Carcinoma	Erdafitinib	EMA
Sensitivity (Supports)	FGFR3 p.G370C	Bladder Urothelial Carcinoma	Erdafitinib	EMA
Sensitivity (Supports)	FGFR3 p.Y373C	Bladder Urothelial Carcinoma	Erdafitinib	EMA
Sensitivity (Supports)	CLDN18.2 >= 75%, HER2-negative	Adenocarcinoma of the Gastroesophageal Junction	Fluorouracil, Oxaliplatin, Zolbetuximab	EMA
Sensitivity (Supports)	CLDN18.2 >= 75%, HER2-negative	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine, Oxaliplatin, Zolbetuximab	EMA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen	EMA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen	EMA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen	EMA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Anastrozole	EMA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole	EMA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole	EMA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Letrozole	EMA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole	EMA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole	EMA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Exemestane	EMA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Exemestane	EMA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Exemestane	EMA
Sensitivity (Supports)	CD19 +, not BCR::ABL1	Acute Lymphoid Leukemia	Blinatumomab	EMA
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Bosutinib	EMA
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Bosutinib	EMA
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Bosutinib	EMA
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Bosutinib	EMA
Sensitivity (Supports)	ER positive, HER2-low	Invasive Breast Carcinoma	Trastuzumab deruxtecan	EMA
Sensitivity (Supports)	HER2-low, PR positive	Invasive Breast Carcinoma	Trastuzumab deruxtecan	EMA
Sensitivity (Supports)	ER positive, HER2-low, PR positive	Invasive Breast Carcinoma	Trastuzumab deruxtecan	EMA
Sensitivity (Supports)	ER positive, HER2-ultralow	Invasive Breast Carcinoma	Trastuzumab deruxtecan	EMA
Sensitivity (Supports)	HER2-ultralow, PR positive	Invasive Breast Carcinoma	Trastuzumab deruxtecan	EMA
Sensitivity (Supports)	ER positive, HER2-ultralow, PR positive	Invasive Breast Carcinoma	Trastuzumab deruxtecan	EMA
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Imatinib	EMA
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Imatinib	EMA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Paclitaxel	EMA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Gemcitabine	EMA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Pemetrexed	EMA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Pemetrexed	EMA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Anastrozole, Goserelin, Ribociclib	EMA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Anastrozole, Goserelin, Ribociclib	EMA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Anastrozole, Goserelin, Ribociclib	EMA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Goserelin, Letrozole, Ribociclib	EMA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Goserelin, Letrozole, Ribociclib	EMA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Goserelin, Letrozole, Ribociclib	EMA
Sensitivity (Supports)	MSI-H	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab	EMA
Sensitivity (Supports)	dMMR	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab	EMA
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Carboplatin, Nivolumab, Paclitaxel	EMA
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Cisplatin, Nivolumab, Pemetrexed	EMA
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Carboplatin, Nivolumab, Pemetrexed	EMA
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Cisplatin, Docetaxel, Nivolumab	EMA
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Amivantamab, Carboplatin, Pemetrexed	EMA
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Amivantamab, Carboplatin, Pemetrexed	EMA
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib	EMA
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib	EMA
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Osimertinib	EMA
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Osimertinib	EMA
Sensitivity (Supports)	PD-L1 (TAP) >= 5%	Esophageal Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Tislelizumab	EMA
Sensitivity (Supports)	PD-L1 (TAP) >= 5%	Esophageal Squamous Cell Carcinoma	Capecitabine, Cisplatin, Tislelizumab	EMA
Sensitivity (Supports)	PD-L1 (TAP) >= 5%	Esophageal Squamous Cell Carcinoma	Fluorouracil, Oxaliplatin, Tislelizumab	EMA
Sensitivity (Supports)	PD-L1 (TAP) >= 5%	Esophageal Squamous Cell Carcinoma	Capecitabine, Oxaliplatin, Tislelizumab	EMA
Sensitivity (Supports)	PD-L1 (TAP) >= 5%	Esophageal Squamous Cell Carcinoma	Cisplatin, Paclitaxel, Tislelizumab	EMA
Sensitivity (Supports)	PD-L1 (TAP) >= 5%	Esophageal Squamous Cell Carcinoma	Oxaliplatin, Paclitaxel, Tislelizumab	EMA
Sensitivity (Supports)	PD-L1 (TAP) >= 5%	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine, Oxaliplatin, Tislelizumab	EMA
Sensitivity (Supports)	PD-L1 (TAP) >= 5%	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Tislelizumab	EMA
Sensitivity (Supports)	MSI-H	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab	EMA
Sensitivity (Supports)	dMMR	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab	EMA
Sensitivity (Supports)	v::ROS1	Non-Small Cell Lung Cancer	Repotrectinib	EMA
Sensitivity (Supports)	v::NTRK1	Any solid tumor	Repotrectinib	EMA
Sensitivity (Supports)	v::NTRK2	Any solid tumor	Repotrectinib	EMA
Sensitivity (Supports)	v::NTRK3	Any solid tumor	Repotrectinib	EMA
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib	EMA
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib	EMA
Sensitivity (Supports)	FOLR1 positive	Ovarian Epithelial Tumor	Mirvetuximab soravtansine	EMA
Sensitivity (Supports)	FOLR1 positive	High-Grade Serous Fallopian Tube Cancer	Mirvetuximab soravtansine	EMA
Sensitivity (Supports)	FOLR1 positive	Peritoneal Serous Carcinoma	Mirvetuximab soravtansine	EMA
Sensitivity (Supports)	ER positive, HER2-negative, PIK3CA Somatic variants	Invasive Breast Carcinoma	Fulvestrant, Inavolisib, Palbociclib	EMA
Sensitivity (Supports)	HER2-negative, PIK3CA Somatic variants, PR positive	Invasive Breast Carcinoma	Fulvestrant, Inavolisib, Palbociclib	EMA
Sensitivity (Supports)	ER positive, HER2-negative, PIK3CA Somatic variants, PR positive	Invasive Breast Carcinoma	Fulvestrant, Inavolisib, Palbociclib	EMA
Sensitivity (Supports)	HER2-positive	Intraductal Papillary Neoplasm of the Bile Duct	Zanidatamab	EMA
Sensitivity (Supports)	HER2-positive	Intracholecystic Papillary Neoplasm	Zanidatamab	EMA
Sensitivity (Supports)	HER2-positive	Cholangiocarcinoma	Zanidatamab	EMA
Sensitivity (Supports)	H3-3A p.K28M	Diffuse Midline Glioma	Dordaviprone	FDA
Sensitivity (Supports)	ER positive, ESR1 activating variants, HER2-negative	Invasive Breast Carcinoma	Imlunestrant	FDA
Sensitivity (Supports)	IDH1 p.R132C	Astrocytoma	Vorasidenib	EMA
Sensitivity (Supports)	IDH1 p.R132G	Astrocytoma	Vorasidenib	EMA
Sensitivity (Supports)	IDH1 p.R132H	Astrocytoma	Vorasidenib	EMA
Sensitivity (Supports)	IDH1 p.R132L	Astrocytoma	Vorasidenib	EMA
Sensitivity (Supports)	IDH1 p.R132S	Astrocytoma	Vorasidenib	EMA
Sensitivity (Supports)	IDH2 p.R172K	Astrocytoma	Vorasidenib	EMA
Sensitivity (Supports)	IDH2 p.R172M	Astrocytoma	Vorasidenib	EMA
Sensitivity (Supports)	IDH2 p.R172G	Astrocytoma	Vorasidenib	EMA
Sensitivity (Supports)	IDH2 p.R172S	Astrocytoma	Vorasidenib	EMA
Sensitivity (Supports)	IDH2 p.R172W	Astrocytoma	Vorasidenib	EMA
Sensitivity (Supports)	IDH1 p.R132C	Oligodendroglioma	Vorasidenib	EMA
Sensitivity (Supports)	IDH1 p.R132G	Oligodendroglioma	Vorasidenib	EMA
Sensitivity (Supports)	IDH1 p.R132H	Oligodendroglioma	Vorasidenib	EMA
Sensitivity (Supports)	IDH1 p.R132L	Oligodendroglioma	Vorasidenib	EMA
Sensitivity (Supports)	IDH1 p.R132S	Oligodendroglioma	Vorasidenib	EMA
Sensitivity (Supports)	IDH2 p.R172K	Oligodendroglioma	Vorasidenib	EMA
Sensitivity (Supports)	IDH2 p.R172M	Oligodendroglioma	Vorasidenib	EMA
Sensitivity (Supports)	IDH2 p.R172G	Oligodendroglioma	Vorasidenib	EMA
Sensitivity (Supports)	IDH2 p.R172S	Oligodendroglioma	Vorasidenib	EMA
Sensitivity (Supports)	IDH2 p.R172W	Oligodendroglioma	Vorasidenib	EMA
Sensitivity (Supports)	HER2-positive, Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Trastuzumab, Tucatinib	FDA
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Quizartinib	FDA
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Quizartinib	FDA
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Cytarabine, Idarubicin, Quizartinib	FDA
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib	FDA
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib	FDA
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib	EMA
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib	EMA
Sensitivity (Supports)	not 17p deletion	Chronic Lymphocytic Leukemia	Ibrutinib	FDA
Sensitivity (Supports)	EGFR activating variants	Non-Small Cell Lung Cancer	Afatinib	HSE
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Alectinib	HSE
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Alectinib	HSE
Sensitivity (Supports)	not BCR::ABL1	Chronic Myelogenous Leukemia	Asciminib	HSE
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Bosutinib	HSE
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Brigatinib	HSE
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Brigatinib	HSE
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Ceritinib	HSE
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Cobimetinib, Vemurafenib	HSE
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Cobimetinib, Vemurafenib	HSE
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Crizotinib	HSE
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Dabrafenib	HSE
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Dabrafenib	HSE
Sensitivity (Supports)	EGFR activating variants	Non-Small Cell Lung Cancer	Dacomitinib	HSE
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Binimetinib, Encorafenib	HSE
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Binimetinib, Encorafenib	HSE
Sensitivity (Supports)	v::ROS1	Non-Small Cell Lung Cancer	Entrectinib	HSE
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Lorlatinib	HSE
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	HSE
Sensitivity (Supports)	ER positive, HER2-positive, PR positive	Invasive Breast Carcinoma	Neratinib	HSE
Sensitivity (Supports)	ER positive, HER2-positive	Invasive Breast Carcinoma	Neratinib	HSE
Sensitivity (Supports)	HER2-positive, PR positive	Invasive Breast Carcinoma	Neratinib	HSE
Sensitivity (Supports)	ER positive, ERBB2 amplification, PR positive	Invasive Breast Carcinoma	Neratinib	HSE
Sensitivity (Supports)	ER positive, ERBB2 amplification	Invasive Breast Carcinoma	Neratinib	HSE
Sensitivity (Supports)	ERBB2 amplification, PR positive	Invasive Breast Carcinoma	Neratinib	HSE
Sensitivity (Supports)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisolone	HSE
Sensitivity (Supports)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisolone	HSE
Sensitivity (Supports)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisolone	HSE
Sensitivity (Supports)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib	HSE
Sensitivity (Supports)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib	HSE
Sensitivity (Supports)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib	HSE
Sensitivity (Supports)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib	HSE
Sensitivity (Supports)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib	HSE
Sensitivity (Supports)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib	HSE
Sensitivity (Supports)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib	HSE
Sensitivity (Supports)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib	HSE
Sensitivity (Supports)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib	HSE
Sensitivity (Supports)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib	HSE
Sensitivity (Supports)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib	HSE
Sensitivity (Supports)	HRD	Ovarian Epithelial Tumor	Bevacizumab, Olaparib	HSE
Sensitivity (Supports)	HRD	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib	HSE
Sensitivity (Supports)	HRD	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib	HSE
Sensitivity (Supports)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Olaparib	HSE
Sensitivity (Supports)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Olaparib	HSE
Sensitivity (Supports)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Olaparib	HSE
Sensitivity (Supports)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Olaparib	HSE
Sensitivity (Supports)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	HSE
Sensitivity (Supports)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	HSE
Sensitivity (Supports)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	HSE
Sensitivity (Supports)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	HSE
Sensitivity (Supports)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib	HSE
Sensitivity (Supports)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib	HSE
Sensitivity (Supports)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib	HSE
Sensitivity (Supports)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib	HSE
Sensitivity (Supports)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Olaparib	HSE
Sensitivity (Supports)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Olaparib	HSE
Sensitivity (Supports)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Olaparib	HSE
Sensitivity (Supports)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Olaparib	HSE
Sensitivity (Supports)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	HSE
Sensitivity (Supports)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	HSE
Sensitivity (Supports)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	HSE
Sensitivity (Supports)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	HSE
Sensitivity (Supports)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib	HSE
Sensitivity (Supports)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib	HSE
Sensitivity (Supports)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib	HSE
Sensitivity (Supports)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib	HSE
Sensitivity (Supports)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Olaparib	HSE
Sensitivity (Supports)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Olaparib	HSE
Sensitivity (Supports)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Olaparib	HSE
Sensitivity (Supports)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Olaparib	HSE
Sensitivity (Supports)	EGFR p.T790M	Non-Small Cell Lung Cancer	Osimertinib	HSE
Sensitivity (Supports)	EGFR activating variants	Non-Small Cell Lung Cancer	Osimertinib	HSE
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Osimertinib	HSE
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Osimertinib	HSE
Sensitivity (Supports)	ABL1 p.T315I	Chronic Myelogenous Leukemia	Ponatinib	HSE
Sensitivity (Supports)	not BCR::ABL1	Acute Lymphoid Leukemia	Ponatinib	HSE
Sensitivity (Supports)	ABL1 p.T315I, not BCR::ABL1	Acute Lymphoid Leukemia	Ponatinib	HSE
Sensitivity (Supports)	BRCA1 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Talazoparib	HSE
Sensitivity (Supports)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Talazoparib	HSE
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib	HSE
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib	HSE
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib	HSE
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib	HSE
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Vemurafenib	HSE
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Vemurafenib	HSE
Sensitivity (Supports)	TP53 Somatic variants	Chronic Lymphocytic Leukemia	Venetoclax	HSE
Sensitivity (Supports)	TP53 deletion	Chronic Lymphocytic Leukemia	Venetoclax	HSE
Sensitivity (Supports)	not 17p deletion	Chronic Lymphocytic Leukemia	Venetoclax	HSE
Sensitivity (Supports)	Wild type TP53	Chronic Lymphocytic Leukemia	Venetoclax	HSE
Sensitivity (Supports)	TP53 Somatic variants	Chronic Lymphocytic Leukemia	Zanubrutinib	HSE
Sensitivity (Supports)	TP53 deletion	Chronic Lymphocytic Leukemia	Zanubrutinib	HSE
Sensitivity (Supports)	not 17p deletion	Chronic Lymphocytic Leukemia	Zanubrutinib	HSE
Sensitivity (Supports)	TP53 Somatic variants	Chronic Lymphocytic Leukemia	Acalabrutinib	HSE
Sensitivity (Supports)	TP53 deletion	Chronic Lymphocytic Leukemia	Acalabrutinib	HSE
Sensitivity (Supports)	not 17p deletion	Chronic Lymphocytic Leukemia	Acalabrutinib	HSE
Sensitivity (Supports)	TP53 Somatic variants	Chronic Lymphocytic Leukemia	Ibrutinib	HSE
Sensitivity (Supports)	TP53 deletion	Chronic Lymphocytic Leukemia	Ibrutinib	HSE
Sensitivity (Supports)	not 17p deletion	Chronic Lymphocytic Leukemia	Ibrutinib	HSE
Sensitivity (Supports)	MSI-H	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab	HSE
Sensitivity (Supports)	dMMR	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab	HSE
Sensitivity (Supports)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Pembrolizumab	HSE
Sensitivity (Supports)	CD274 amplification, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Pembrolizumab	HSE
Sensitivity (Supports)	PD-L1 (CPS) >= 10	Bladder Urothelial Carcinoma	Pembrolizumab	HSE
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Head and Neck Squamous Cell Carcinoma	Pembrolizumab	HSE
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Pembrolizumab	HSE
Sensitivity (Supports)	MSI-H	Colorectal Adenocarcinoma	Pembrolizumab	HSE
Sensitivity (Supports)	dMMR	Colorectal Adenocarcinoma	Pembrolizumab	HSE
Sensitivity (Supports)	v::NTRK1	Any solid tumor	Larotrectinib	HSE
Sensitivity (Supports)	v::NTRK2	Any solid tumor	Larotrectinib	HSE
Sensitivity (Supports)	v::NTRK3	Any solid tumor	Larotrectinib	HSE
Sensitivity (Supports)	v::NTRK1	Any solid tumor	Larotrectinib	HSE
Sensitivity (Supports)	v::NTRK2	Any solid tumor	Larotrectinib	HSE
Sensitivity (Supports)	v::NTRK3	Any solid tumor	Larotrectinib	HSE
Sensitivity (Supports)	EGFR activating variants	Non-Small Cell Lung Cancer	Erlotinib	HSE
Sensitivity (Supports)	EGFR activating variants	Non-Small Cell Lung Cancer	Erlotinib	HSE
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab emtansine	HSE
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Letrozole, Ribociclib	HSE
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Ribociclib	HSE
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Ribociclib	HSE
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Letrozole, Ribociclib	HSE
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Ribociclib	HSE
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Ribociclib	HSE
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant, Ribociclib	HSE
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Ribociclib	HSE
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Ribociclib	HSE
Sensitivity (Supports)	CD22 +	Acute Lymphoid Leukemia	Inotuzumab ozogamicin	HSE
Sensitivity (Supports)	CD22 +, not BCR::ABL1	Acute Lymphoid Leukemia	Inotuzumab ozogamicin	HSE
Sensitivity (Supports)	CD19 +, not BCR::ABL1	Acute Lymphoid Leukemia	Blinatumomab	HSE
Sensitivity (Supports)	CD30 +	Hodgkin Lymphoma	Brentuximab vedotin, Cisplatin, Cytarabine, Etoposide	HSE
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab	HSE
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab	HSE
Sensitivity (Supports)	CD33 +	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Gemtuzumab ozogamicin	HSE
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Pembrolizumab, Pemetrexed	HSE
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Pembrolizumab, Pemetrexed	HSE
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Durvalumab	HSE
Sensitivity (Supports)	PD-L1 >= 5%	Bladder Urothelial Carcinoma	Atezolizumab	HSE
Sensitivity (Supports)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab	HSE
Sensitivity (Supports)	PD-L1 >= 10% TIIC, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab	HSE
Sensitivity (Supports)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab	HSE
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab emtansine	HSE
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Head and Neck Squamous Cell Carcinoma	Carboplatin, Fluorouracil, Pembrolizumab	HSE
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Head and Neck Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Pembrolizumab	HSE
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Paclitaxel	HSE
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Pemetrexed	HSE
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Ipilimumab, Nivolumab, Pemetrexed	HSE
Sensitivity (Supports)	ER negative, HER2-negative, PD-L1 >= 1%, PR negative	Invasive Breast Carcinoma	Atezolizumab, Nab-paclitaxel	HSE
Sensitivity (Supports)	CD19 +, not BCR::ABL1	Acute Lymphoid Leukemia	Blinatumomab	HSE
Sensitivity (Supports)	CD19 +, not BCR::ABL1	Acute Lymphoid Leukemia	Blinatumomab	HSE
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Paclitaxel, Pertuzumab, Trastuzumab	HSE
Sensitivity (Supports)	CD30 +	Cutaneous T-cell Lymphoma	Brentuximab vedotin	HSE
Sensitivity (Supports)	CD30 +	Hodgkin Lymphoma	Brentuximab vedotin	HSE
Sensitivity (Supports)	CD30 +	Hodgkin Lymphoma	Brentuximab vedotin	HSE
Sensitivity (Supports)	CD30 +	Hodgkin Lymphoma	Brentuximab vedotin	HSE
Sensitivity (Supports)	CD30 +, HER2-negative	Hodgkin Lymphoma	Brentuximab vedotin, Carboplatin, Etoposide, Ifosfamide	HSE
Sensitivity (Supports)	PD-L1 (CPS) >= 10	Esophageal Adenocarcinoma	Cisplatin, Fluorouracil, Pembrolizumab	HSE
Sensitivity (Supports)	HER2-negative, PD-L1 (CPS) >= 10	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Pembrolizumab	HSE
Sensitivity (Supports)	PD-L1 >= 1%	Esophageal Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Nivolumab	HSE
Sensitivity (Supports)	PD-L1 >= 5%	Bladder Urothelial Carcinoma	Atezolizumab	HSE
Sensitivity (Supports)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab	HSE
Sensitivity (Supports)	PD-L1 >= 10% TIIC, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab	HSE
Sensitivity (Supports)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab	HSE
Sensitivity (Supports)	HER2-negative, PD-L1 (CPS) >= 10	Adenocarcinoma of the Gastroesophageal Junction	Fluorouracil, Oxaliplatin, Pembrolizumab	HSE
Sensitivity (Supports)	not BCR::ABL1	Acute Lymphoid Leukemia	Blinatumomab	HSE
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Paclitaxel, Pertuzumab, Trastuzumab	HSE
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Paclitaxel, Pertuzumab, Trastuzumab	HSE
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab	HSE
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab	HSE
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Pertuzumab, Trastuzumab, Vinorelbine	HSE
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Pertuzumab, Trastuzumab, Vinorelbine	HSE
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Pertuzumab, Trastuzumab	HSE
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Pertuzumab, Trastuzumab	HSE
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Carboplatin, Nivolumab, Paclitaxel	HSE
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Carboplatin, Gemcitabine, Nivolumab	HSE
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Cisplatin, Gemcitabine, Nivolumab	HSE
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Carboplatin, Nivolumab, Pemetrexed	HSE
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Cisplatin, Nivolumab, Pemetrexed	HSE
Sensitivity (Supports)	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Pembrolizumab	HSE
Sensitivity (Supports)	HER2-negative	Invasive Breast Carcinoma	Bevacizumab, Paclitaxel	HSE
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Capecitabine, Lapatinib	HSE
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab	HSE
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Paclitaxel, Trastuzumab	HSE
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Trastuzumab	HSE
Sensitivity (Supports)	ER positive, ERBB2 amplification, PR positive	Invasive Breast Carcinoma	Anastrozole, Trastuzumab	HSE
Sensitivity (Supports)	ER positive, ERBB2 amplification	Invasive Breast Carcinoma	Anastrozole, Trastuzumab	HSE
Sensitivity (Supports)	ERBB2 amplification, PR positive	Invasive Breast Carcinoma	Anastrozole, Trastuzumab	HSE
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab	HSE
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Paclitaxel, Trastuzumab	HSE
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Trastuzumab	HSE
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Trastuzumab	HSE
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Doxorubicin, Paclitaxel, Trastuzumab	HSE
Sensitivity (Supports)	ER positive, PR positive	Invasive Breast Carcinoma	Letrozole	HSE
Sensitivity (Supports)	ER positive	Invasive Breast Carcinoma	Letrozole	HSE
Sensitivity (Supports)	PR positive	Invasive Breast Carcinoma	Letrozole	HSE
Sensitivity (Supports)	ER positive, PR positive	Invasive Breast Carcinoma	Letrozole	HSE
Sensitivity (Supports)	ER positive	Invasive Breast Carcinoma	Letrozole	HSE
Sensitivity (Supports)	PR positive	Invasive Breast Carcinoma	Letrozole	HSE
Sensitivity (Supports)	ER positive, PR positive	Invasive Breast Carcinoma	Exemestane	HSE
Sensitivity (Supports)	ER positive	Invasive Breast Carcinoma	Exemestane	HSE
Sensitivity (Supports)	PR positive	Invasive Breast Carcinoma	Exemestane	HSE
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Exemestane	HSE
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Exemestane	HSE
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Exemestane	HSE
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Pertuzumab, Trastuzumab	HSE
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Pertuzumab, Trastuzumab	HSE
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Paclitaxel, Pertuzumab, Trastuzumab	HSE
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Pertuzumab, Trastuzumab	HSE
Sensitivity (Supports)	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Pembrolizumab	HSE
Sensitivity (Supports)	PD-L1 >= 1%	Esophageal Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Nivolumab	HSE
Sensitivity (Supports)	PD-L1 >= 1%	Esophageal Squamous Cell Carcinoma	Fluorouracil, Nivolumab, Oxaliplatin	HSE
Sensitivity (Supports)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Pembrolizumab	HSE
Sensitivity (Supports)	PD-L1 (CPS) >= 10	Bladder Urothelial Carcinoma	Pembrolizumab	HSE
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Head and Neck Squamous Cell Carcinoma	Pembrolizumab	HSE
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Pembrolizumab	HSE
Sensitivity (Supports)	MSI-H	Colorectal Adenocarcinoma	Pembrolizumab	HSE
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab	HSE
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Carboplatin, Paclitaxel, Pembrolizumab	HSE
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Midostaurin	HSE
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	HSE
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Cisplatin, Gemcitabine, Nivolumab	HSE
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Carboplatin, Nivolumab, Paclitaxel	HSE
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Carboplatin, Gemcitabine, Nivolumab	HSE
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Cisplatin, Nivolumab, Pemetrexed	HSE
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Carboplatin, Nivolumab, Pemetrexed	HSE
Sensitivity (Supports)	PD-L1 >= 5%	Bladder Urothelial Carcinoma	Atezolizumab	HSE
Sensitivity (Supports)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab	HSE
Sensitivity (Supports)	PD-L1 >= 10% TIIC, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab	HSE
Sensitivity (Supports)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab	HSE
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Durvalumab	HSE
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine	HSE
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine	HSE
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine	HSE
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Etoposide, Prednisolone, Rituximab, Vincristine	HSE
Sensitivity (Supports)	CD30 +	Hodgkin Lymphoma	Bendamustine, Brentuximab vedotin	HSE
Sensitivity (Supports)	CD20 +	Follicular Lymphoma	Cyclophosphamide, Prednisolone, Rituximab, Vincristine	HSE
Sensitivity (Supports)	CD20 +	Follicular Lymphoma	Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine	HSE
Sensitivity (Supports)	CD20 +	Follicular Lymphoma	Chlorambucil, Mitoxantrone, Prednisolone, Rituximab	HSE
Sensitivity (Supports)	CD20 +	Follicular Lymphoma	Cyclophosphamide, Doxorubicin, Etoposide, Interferon Alpha, Prednisolone, Rituximab	HSE
Sensitivity (Supports)	CD20 +	Follicular Lymphoma	Rituximab	HSE
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Rituximab	HSE
Sensitivity (Supports)	CD20 +	Follicular Lymphoma	Rituximab	HSE
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Rituximab	HSE
Sensitivity (Supports)	CD20 +	Follicular Lymphoma	Rituximab	HSE
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Rituximab	HSE
Sensitivity (Supports)	CD20 +	Diffuse Large B-Cell Lymphoma	Cyclophosphamide, Doxorubicin, Etoposide, Prednisolone, Rituximab, Vincristine	HSE
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Etoposide, Prednisolone, Rituximab, Vincristine	HSE
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Prednisolone, Rituximab, Vincristine	HSE
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Prednisolone, Rituximab, Vincristine	HSE
Sensitivity (Supports)	CD20 +	Follicular Lymphoma	Rituximab	HSE
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Rituximab	HSE
Sensitivity (Supports)	MET Exon 14 (Splice Site)	Non-Small Cell Lung Cancer	Tepotinib	HSE
Sensitivity (Supports)	MET Exon 14 (Deletion)	Non-Small Cell Lung Cancer	Tepotinib	HSE
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab deruxtecan	HSE
Sensitivity (Supports)	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Pembrolizumab	HSE
Sensitivity (Supports)	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Pembrolizumab	HSE
Sensitivity (Supports)	v::RET	Medullary Thyroid Cancer	Vandetanib	HSE
Sensitivity (Supports)	PML::RARA	APL with PML-RARA	Arsenic trioxide	HSE
Sensitivity (Supports)	PML::RARA	APL with PML-RARA	Arsenic trioxide	HSE
Sensitivity (Supports)	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Sacituzumab govitecan	HSE
Sensitivity (Supports)	v::NTRK1	Any solid tumor	Entrectinib	HSE
Sensitivity (Supports)	v::NTRK2	Any solid tumor	Entrectinib	HSE
Sensitivity (Supports)	v::NTRK3	Any solid tumor	Entrectinib	HSE
Sensitivity (Supports)	ER positive	Invasive Breast Carcinoma	Letrozole	HSE
Sensitivity (Supports)	PR positive	Invasive Breast Carcinoma	Letrozole	HSE
Sensitivity (Supports)	ER positive, PR positive	Invasive Breast Carcinoma	Letrozole	HSE
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen	HSE
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen	HSE
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen	HSE
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole	HSE
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Letrozole	HSE
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole	HSE
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Anastrozole	HSE
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole	HSE
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole	HSE
Sensitivity (Supports)	ER positive	Invasive Breast Carcinoma	Anastrozole	HPRA
Sensitivity (Supports)	PR positive	Invasive Breast Carcinoma	Anastrozole	HPRA
Sensitivity (Supports)	ER positive, PR positive	Invasive Breast Carcinoma	Anastrozole	HPRA
Sensitivity (Supports)	ER positive	Invasive Breast Carcinoma	Anastrozole	HPRA
Sensitivity (Supports)	PR positive	Invasive Breast Carcinoma	Anastrozole	HPRA
Sensitivity (Supports)	ER positive, PR positive	Invasive Breast Carcinoma	Anastrozole	HPRA
Sensitivity (Supports)	ER positive	Invasive Breast Carcinoma	Anastrozole	HPRA
Sensitivity (Supports)	PR positive	Invasive Breast Carcinoma	Anastrozole	HPRA
Sensitivity (Supports)	ER positive, PR positive	Invasive Breast Carcinoma	Anastrozole	HPRA
Sensitivity (Supports)	ER positive	Invasive Breast Carcinoma	Exemestane	HPRA
Sensitivity (Supports)	ER positive	Invasive Breast Carcinoma	Letrozole	HPRA
Sensitivity (Supports)	PR positive	Invasive Breast Carcinoma	Letrozole	HPRA
Sensitivity (Supports)	ER positive, PR positive	Invasive Breast Carcinoma	Letrozole	HPRA
Sensitivity (Supports)	ER positive	Invasive Breast Carcinoma	Letrozole	HPRA
Sensitivity (Supports)	PR positive	Invasive Breast Carcinoma	Letrozole	HPRA
Sensitivity (Supports)	ER positive, PR positive	Invasive Breast Carcinoma	Letrozole	HPRA
Sensitivity (Supports)	ER positive	Invasive Breast Carcinoma	Letrozole	HPRA
Sensitivity (Supports)	PR positive	Invasive Breast Carcinoma	Letrozole	HPRA
Sensitivity (Supports)	ER positive, PR positive	Invasive Breast Carcinoma	Letrozole	HPRA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Letrozole	HPRA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole	HPRA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole	HPRA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Anastrozole, Goserelin, Ribociclib	HSE
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Anastrozole, Goserelin, Ribociclib	HSE
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Anastrozole, Goserelin, Ribociclib	HSE
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Goserelin, Letrozole, Ribociclib	HSE
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Goserelin, Letrozole, Ribociclib	HSE
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Goserelin, Letrozole, Ribociclib	HSE
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Quizartinib	HSE
Sensitivity (Supports)	FGFR2::v	Cholangiocarcinoma	Elacestrant	HSE
Sensitivity (Supports)	FGFR2 rearrangements	Cholangiocarcinoma	Elacestrant	HSE
Sensitivity (Supports)	BRCA1 pathogenic variants	Pancreatic Adenocarcinoma	Olaparib	HSE
Sensitivity (Supports)	BRCA2 pathogenic variants	Pancreatic Adenocarcinoma	Olaparib	HSE
Sensitivity (Supports)	BRCA1 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib	HSE
Sensitivity (Supports)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib	HSE
Sensitivity (Supports)	MSI-H	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab	HSE
Sensitivity (Supports)	dMMR	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab	HSE
Sensitivity (Supports)	PD-L1 >= 1%	Bladder Urothelial Carcinoma	Nivolumab	HSE
Sensitivity (Supports)	IDH1 p.R132C	Cholangiocarcinoma	Ivosidenib	HSE
Sensitivity (Supports)	IDH1 p.R132G	Cholangiocarcinoma	Ivosidenib	HSE
Sensitivity (Supports)	IDH1 p.R132H	Cholangiocarcinoma	Ivosidenib	HSE
Sensitivity (Supports)	IDH1 p.R132L	Cholangiocarcinoma	Ivosidenib	HSE
Sensitivity (Supports)	IDH1 p.R132S	Cholangiocarcinoma	Ivosidenib	HSE
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Gilteritinib	HSE
Sensitivity (Supports)	FLT3 p.D835Y	Acute Myeloid Leukemia	Gilteritinib	HSE
Sensitivity (Supports)	FGFR3::TACC3	Bladder Urothelial Carcinoma	Erdafitinib	HSE
Sensitivity (Supports)	FGFR3::BAIAP2L1	Bladder Urothelial Carcinoma	Erdafitinib	HSE
Sensitivity (Supports)	FGFR3 p.R248C	Bladder Urothelial Carcinoma	Erdafitinib	HSE
Sensitivity (Supports)	FGFR3 p.S249C	Bladder Urothelial Carcinoma	Erdafitinib	HSE
Sensitivity (Supports)	FGFR3 p.G370C	Bladder Urothelial Carcinoma	Erdafitinib	HSE
Sensitivity (Supports)	FGFR3 p.Y373C	Bladder Urothelial Carcinoma	Erdafitinib	HSE
Sensitivity (Supports)	HER2-low	Invasive Breast Carcinoma	Trastuzumab deruxtecan	HSE
Sensitivity (Supports)	TP53 deletion	Chronic Lymphocytic Leukemia	Idelalisib, Rituximab	HSE
Sensitivity (Supports)	TP53 Somatic variants	Chronic Lymphocytic Leukemia	Idelalisib, Rituximab	HSE
Sensitivity (Supports)	not 17p deletion	Chronic Lymphocytic Leukemia	Idelalisib, Rituximab	HSE
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Quizartinib	EMA
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Quizartinib	EMA
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Cytarabine, Idarubicin, Quizartinib	EMA
Sensitivity (Supports)	EGFR Somatic variants	Non-Small Cell Lung Cancer	Atezolizumab	HSE
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Atezolizumab	HSE
Sensitivity (Supports)	EGFR Somatic variants	Non-Small Cell Lung Cancer	Atezolizumab	HSE
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Atezolizumab	HSE
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab	HSE
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab	HSE
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab	HSE
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab	HSE
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Pertuzumab, Trastuzumab	HSE
Sensitivity (Supports)	NPM1 p.W288Cfs*12	Acute Myeloid Leukemia	Ziftomenib	FDA
Sensitivity (Supports)	ERBB2 TKD activating variants	Lung Non-Squamous Non-Small Cell Carcinoma	Sevabertinib	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Pertuzumab, Trastuzumab deruxtecan	FDA
Sensitivity (Supports)	NPM1 p.W288Cfs*12	Acute Myeloid Leukemia	Revumenib	FDA
Sensitivity (Supports)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Tislelizumab	FDA
Sensitivity (Supports)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Capecitabine, Cisplatin, Tislelizumab	FDA
Sensitivity (Supports)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Fluorouracil, Oxaliplatin, Tislelizumab	FDA
Sensitivity (Supports)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Capecitabine, Oxaliplatin, Tislelizumab	FDA
Sensitivity (Supports)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Cisplatin, Paclitaxel, Tislelizumab	FDA
Sensitivity (Supports)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Oxaliplatin, Paclitaxel, Tislelizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Tislelizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Capecitabine, Cisplatin, Tislelizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Fluorouracil, Oxaliplatin, Tislelizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Capecitabine, Oxaliplatin, Tislelizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Cisplatin, Paclitaxel, Tislelizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Oxaliplatin, Paclitaxel, Tislelizumab	FDA
Sensitivity (Supports)	HER2-negative, PD-L1 (TAP) >= 1%	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine, Oxaliplatin, Tislelizumab	FDA
Sensitivity (Supports)	HER2-negative, PD-L1 (TAP) >= 1%	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Tislelizumab	FDA
Sensitivity (Supports)	HER2-negative, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine, Oxaliplatin, Tislelizumab	FDA
Sensitivity (Supports)	HER2-negative, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Tislelizumab	FDA
Sensitivity (Supports)	NPM1 p.W288Cfs*12	Acute Lymphoid Leukemia	Revumenib	FDA
Sensitivity (Supports)	NPM1 p.W288Cfs*12	Burkitt Lymphoma	Revumenib	FDA
Sensitivity (Supports)	NPM1 p.W288Cfs*12	Acute Leukemias of Ambiguous Lineage	Revumenib	FDA
Sensitivity (Supports)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone	FDA
Sensitivity (Supports)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib, Fluorouracil, Irinotecan	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Ovarian Epithelial Tumor	Paclitaxel, Pembrolizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Ovarian Epithelial Tumor	Bevacizumab, Paclitaxel, Pembrolizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	High-Grade Serous Fallopian Tube Cancer	Paclitaxel, Pembrolizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Paclitaxel, Pembrolizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Peritoneal Serous Carcinoma	Paclitaxel, Pembrolizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Peritoneal Serous Carcinoma	Bevacizumab, Paclitaxel, Pembrolizumab	FDA
Sensitivity (Supports)	ER positive, ESR1 activating variants, HER2-negative	Invasive Breast Carcinoma	Imlunestrant	EMA
Sensitivity (Supports)	VHL pathogenic variants	Renal Cell Carcinoma	Belzutifan	EMA
Sensitivity (Supports)	VHL pathogenic variants	Central Nervous System Hemangioblastoma	Belzutifan	EMA
Sensitivity (Supports)	VHL pathogenic variants	Pancreatic Neuroendocrine Tumor	Belzutifan	EMA
Sensitivity (Supports)	VHL pathogenic variants	Renal Cell Carcinoma	Belzutifan	FDA
Sensitivity (Supports)	VHL pathogenic variants	Central Nervous System Hemangioblastoma	Belzutifan	FDA
Sensitivity (Supports)	VHL pathogenic variants	Pancreatic Neuroendocrine Tumor	Belzutifan	FDA
Sensitivity (Supports)	CD30 +	Hodgkin Lymphoma	Brentuximab vedotin, Cyclophosphamide, Dacarbazine, Dexamethasone, Doxorubicin, Etoposide	EMA
Sensitivity (Supports)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone	EMA
Sensitivity (Supports)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone	EMA
Sensitivity (Supports)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone	EMA
Sensitivity (Supports)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone	EMA
Sensitivity (Supports)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisolone	EMA
Sensitivity (Supports)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisolone	EMA
Sensitivity (Supports)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisolone	EMA
Sensitivity (Supports)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisolone	EMA
Sensitivity (Supports)	CD22 +	Acute Lymphoid Leukemia	Inotuzumab ozogamicin	EMA
Sensitivity (Supports)	CD22 +, not BCR::ABL1	Acute Lymphoid Leukemia	Inotuzumab ozogamicin	EMA
Sensitivity (Supports)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib, Fluorouracil, Oxaliplatin	EMA
Sensitivity (Supports)	HER2-positive	Any solid tumor	Trastuzumab deruxtecan	EMA
Sensitivity (Supports)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib, Fluorouracil, Oxaliplatin	EMA
Sensitivity (Supports)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib	EMA
Sensitivity (Supports)	BCR::ABL1	Acute Lymphoid Leukemia	Cytarabine, Dexamethasone, Methotrexate, Ponatinib, Prednisone, Vincristine	EMA
Sensitivity (Supports)	ABL1 p.T315I	Chronic Myelogenous Leukemia	Ponatinib	EMA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Ovarian Epithelial Tumor	Paclitaxel, Pembrolizumab	EMA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Ovarian Epithelial Tumor	Bevacizumab, Paclitaxel, Pembrolizumab	EMA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	High-Grade Serous Fallopian Tube Cancer	Paclitaxel, Pembrolizumab	EMA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Paclitaxel, Pembrolizumab	EMA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Peritoneal Serous Carcinoma	Paclitaxel, Pembrolizumab	EMA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Peritoneal Serous Carcinoma	Bevacizumab, Paclitaxel, Pembrolizumab	EMA
Sensitivity (Supports)	BRAF p.V600E	Differentiated Thyroid Gland Carcinoma	Dabrafenib, Trametinib	EMA
Sensitivity (Supports)	ABL1 p.T315I, BCR::ABL1	Chronic Myelogenous Leukemia	Asciminib	EMA
Sensitivity (Supports)	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Sacituzumab govitecan	EMA
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Aumolertinib	EMA
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Aumolertinib	EMA
Sensitivity (Supports)	EGFR p.T790M	Non-Small Cell Lung Cancer	Aumolertinib	EMA
Sensitivity (Supports)	BRAF rearrangements	Low-Grade Glioma, NOS	Tovorafenib	EMA
Sensitivity (Supports)	v::BRAF	Low-Grade Glioma, NOS	Tovorafenib	EMA
Sensitivity (Supports)	BRAF p.V600E	Low-Grade Glioma, NOS	Tovorafenib	EMA
Sensitivity (Supports)	BRAF p.V600K	Low-Grade Glioma, NOS	Tovorafenib	EMA
Sensitivity (Supports)	ER positive, ESR1 activating variants, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Camizestrant	EMA
Sensitivity (Supports)	ER positive, ESR1 activating variants, HER2-negative	Invasive Breast Carcinoma	Camizestrant, Palbociclib	EMA
Sensitivity (Supports)	ER positive, ESR1 activating variants, HER2-negative	Invasive Breast Carcinoma	Camizestrant, Ribociclib	EMA
Sensitivity (Supports)	t(11;14)	Mantle Cell Lymphoma	Ibrutinib	HSE
Sensitivity (Supports)	CD20 +	Follicular Lymphoma	Bendamustine, Obinutuzumab	HSE
Sensitivity (Supports)	CD20 +	Follicular Lymphoma	Bendamustine, Obinutuzumab	HSE
Sensitivity (Supports)	PD-L1 >= 1%	Bladder Urothelial Carcinoma	Nivolumab	HSE
Sensitivity (Supports)	CD20 +	Follicular Lymphoma	Cyclophosphamide, Doxorubicin, Obinutuzumab, Prednisolone, Vincristine	HSE
Sensitivity (Supports)	CD20 +	Follicular Lymphoma	Cyclophosphamide, Obinutuzumab, Prednisolone, Vincristine	HSE
Sensitivity (Supports)	HER2-negative, PD-L1 (CPS) >= 5	Stomach Adenocarcinoma	Capecitabine, Nivolumab, Oxaliplatin	HSE
Sensitivity (Supports)	HER2-negative, PD-L1 (CPS) >= 5	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine, Nivolumab, Oxaliplatin	HSE
Sensitivity (Supports)	HER2-negative, PD-L1 (CPS) >= 5	Esophageal Adenocarcinoma	Capecitabine, Nivolumab, Oxaliplatin	HSE
Sensitivity (Supports)	BCR::ABL1	Acute Lymphoid Leukemia	Daunorubicin, Dexamethasone, Imatinib, Methotrexate, Vincristine	HSE
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Cytarabine, Quizartinib	HSE
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Quizartinib	HSE
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Cytarabine, Idarubicin, Quizartinib	HSE
Sensitivity (Supports)	PD-L1 (TAP) >= 5%	Esophageal Squamous Cell Carcinoma	Capecitabine, Oxaliplatin, Tislelizumab	HSE
Sensitivity (Supports)	PD-L1 (TAP) >= 5%	Esophageal Squamous Cell Carcinoma	Fluorouracil, Oxaliplatin, Tislelizumab	HSE
Sensitivity (Supports)	dMMR	Endometrial Carcinoma	Carboplatin, Dostarlimab, Paclitaxel	HSE
Sensitivity (Supports)	MSI-H	Endometrial Carcinoma	Carboplatin, Dostarlimab, Paclitaxel	HSE
Sensitivity (Supports)	CCND1	Mantle Cell Lymphoma	Ibrutinib	HSE
Sensitivity (Supports)	BCR::ABL1, CD20 +	Acute Lymphoid Leukemia	Daunorubicin, Dexamethasone, Imatinib, Methotrexate, Rituximab, Vincristine	HSE
Sensitivity (Supports)	CD20 +	Acute Lymphoid Leukemia	Daunorubicin, Dexamethasone, Methotrexate, Rituximab, Vincristine	HSE
Sensitivity (Supports)	HER2-negative, PD-L1 (CPS) >= 5	Esophageal Adenocarcinoma	Fluorouracil, Nivolumab, Oxaliplatin	HSE
Sensitivity (Supports)	HER2-negative, PD-L1 (CPS) >= 5	Adenocarcinoma of the Gastroesophageal Junction	Fluorouracil, Nivolumab, Oxaliplatin	HSE
Sensitivity (Supports)	not 17p deletion	Chronic Lymphocytic Leukemia	Venetoclax	HSE
Sensitivity (Supports)	HER2-negative, PD-L1 (CPS) >= 5	Stomach Adenocarcinoma	Fluorouracil, Nivolumab, Oxaliplatin	HSE
Sensitivity (Supports)	dMMR	Colorectal Adenocarcinoma	Pembrolizumab	HSE
Sensitivity (Supports)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib	HSE
Sensitivity (Supports)	ERBB2 amplification	Invasive Breast Carcinoma	Doxorubicin, Paclitaxel, Trastuzumab	HSE
Sensitivity (Supports)	ERBB2 amplification	Invasive Breast Carcinoma	Docetaxel, Trastuzumab	HSE
Sensitivity (Supports)	ERBB2 amplification	Invasive Breast Carcinoma	Paclitaxel, Trastuzumab	HSE
Sensitivity (Supports)	ERBB2 amplification	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Trastuzumab	HSE
Sensitivity (Supports)	ERBB2 amplification	Invasive Breast Carcinoma	Capecitabine, Lapatinib	HSE
Sensitivity (Supports)	ERBB2 amplification	Invasive Breast Carcinoma	Trastuzumab	HSE
Sensitivity (Supports)	ERBB2 amplification	Invasive Breast Carcinoma	Trastuzumab	HSE
Sensitivity (Supports)	ERBB2 amplification	Invasive Breast Carcinoma	Paclitaxel, Trastuzumab	HSE
Sensitivity (Supports)	ERBB2 amplification	Invasive Breast Carcinoma	Docetaxel, Trastuzumab	HSE
Sensitivity (Supports)	ER positive, HER2-positive, PR positive	Invasive Breast Carcinoma	Anastrozole, Trastuzumab	HSE
Sensitivity (Supports)	ER positive, HER2-positive	Invasive Breast Carcinoma	Anastrozole, Trastuzumab	HSE
Sensitivity (Supports)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisolone	HSE
Sensitivity (Supports)	HER2-positive, PR positive	Invasive Breast Carcinoma	Anastrozole, Trastuzumab	EMA
Sensitivity (Supports)	HER2-positive, PR positive	Invasive Breast Carcinoma	Anastrozole, Trastuzumab	HSE
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Bosutinib	HSE
Sensitivity (Supports)	ER positive, ERBB2 amplification, PR positive	Invasive Breast Carcinoma	Anastrozole, Trastuzumab	EMA
Sensitivity (Supports)	ER positive, ERBB2 amplification	Invasive Breast Carcinoma	Anastrozole, Trastuzumab	EMA
Sensitivity (Supports)	ERBB2 amplification, PR positive	Invasive Breast Carcinoma	Anastrozole, Trastuzumab	EMA
Sensitivity (Supports)	PD-L1 (CPS) >= 10	Esophageal Adenocarcinoma	Dordaviprone	HSE